10-Q

UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION 

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2015

☐  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from________ to ___________

Commission File No. 000-54090

CAREVIEW COMMUNICATIONS, INC. 

(Exact name of registrant as specified in its charter)

Nevada	95-4659068
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)
405 State Highway 121, Suite B-240, Lewisville, TX 75067	(972) 943-6050
(Address of principal executive offices)	(Registrant’s Telephone Number)

N/A

 (Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.   Yes  ☒    No  ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).   Yes  ☒    No  ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer  ☐ Accelerated filer  ☐ Non-accelerated filer  ☐ Smaller reporting company  ☒

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes  ☐    No  ☒

The number of shares outstanding of each of the issuer’s classes of Common Stock as of August 14, 2015 was 139,380,748.

CAREVIEW COMMUNICATIONS, INC. AND SUBSIDIARIES

TABLE OF CONTENTS

			Page
PART I - FINANCIAL INFORMATION
	Item. 1	Financial Statements
		Condensed Consolidated Balance Sheets as of June 30, 2015 (Unaudited) and December 31, 2014	3
		Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2015 and 2014 (Unaudited)	4
		Condensed Consolidated Statement of Stockholders' Deficit for the period from January 1, 2015 to June 30, 2015 (Unaudited)	5
		Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2015 and 2014 (Unaudited)	6
		Notes to the Condensed Consolidated Financial Statements	7
	Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	22
	Item 3.	Quantitative and Qualitative Disclosures about Market Risk	30
	Item 4.	Controls and Procedures	30
PART II - OTHER INFORMATION
	Item 1.	Legal Proceedings	30
	Item 1A.	Risk Factors	30
	Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	30
	Item 3.	Defaults Upon Senior Securities	30
	Item 4.	Mine Safety Disclosures	31
	Item 5.	Other Information	31
	Item 6.	Exhibits	31

2

CAREVIEW COMMUNICATIONS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

	June 30,
	2015			December 31,
	(unaudited)			2014
ASSETS
Current Assets:
Cash	$	5,245,503		$	2,546,262
Accounts receivable, net of allowance for doubtful accounts		889,731			680,143
Other current assets		350,216			276,910
Total current assets		6,485,450			3,503,315
Property and equipment, net		5,042,805			5,344,792
Other Assets:
Intangible assets, net		293,958			261,283
Other assets		3,188,107			832,930
Total other assets		3,482,065			1,094,213
Total assets	$	15,010,320		$	9,942,320
LIABILITIES AND STOCKHOLDERS' DEFICIT
Current Liabilities:
Accounts payable	$	511,294		$	244,782
Notes payable		441,594			441,594
Mandatorily redeemable equity in joint ventures		441,594			441,594
Accrued interest		225,226			191,596
Other current liabilities		1,121,259			791,284
Total current liabilities		2,740,967			2,110,850
Long-term Liabilities:
Senior secured convertible notes, net of debt discount and debt issuance costs of $22,467,023 and $21,457,970, respectively		30,914,930			22,834,641
Fair value of warrant liability		314,818			301,864
Total long-term liabilities		31,229,748			23,136,505
Total liabilities		33,970,715			25,247,355
Commitments and Contingencies
Stockholders' Deficit:
Preferred stock - par value $0.001; 20,000,000 shares authorized; no shares issued and outstanding		—			—
Common stock - par value $0.001; 300,000,000 shares authorized; 139,380,748 issued and outstanding		139,381			139,381
Additional paid in capital		80,570,085			76,502,913
Accumulated deficit		(99,200,548	)		(91,510,720	)
Total CareView Communications Inc. stockholders' deficit		(18,491,082	)		(14,868,426	)
Noncontrolling interest		(469,313	)		(436,609	)
Total stockholders' deficit		(18,960,395	)		(15,305,035	)
Total liabilities and stockholders' deficit	$	15,010,320		$	9,942,320

3

CAREVIEW COMMUNICATIONS INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2015 AND 2014

(Unaudited)

	Three Months Ended						Six Months Ended
	June 30, 2015			June 30, 2014			June 30, 2015			June 30, 2014
Revenues, net	$	1,266,391		$	698,129		$	2,266,945		$	1,317,538
Operating expenses:
Network operations		1,304,973			811,178			2,135,067			1,412,400
General and administration		923,056			805,081			1,761,365			1,607,058
Sales and marketing		233,154			155,089			430,776			363,547
Research and development		306,445			232,168			531,641			400,829
Depreciation and amortization		442,248			407,376			858,152			806,708
Total operating expense		3,209,876			2,410,892			5,717,001			4,590,542
Operating loss		(1,943,485	)		(1,712,763	)		(3,450,056	)		(3,273,004	)
Other income and (expense)
Interest expense		(2,217,846	)		(2,054,421	)		(4,263,747	)		(4,031,872	)
Change in fair value of warrant liability		225,147			55,801			(12,954	)		(577,341	)
Interest income		1,342			963			2,485			1,962
Other income		615			549			1,740			1,843
Total other income (expense)		(1,990,742	)		(1,997,108	)		(4,272,476	)		(4,605,408	)
Loss before taxes		(3,934,227	)		(3,709,871	)		(7,722,532	)		(7,878,412	)
Provision for income taxes		—			—			—			—
Net loss		(3,934,227	)		(3,709,871	)		(7,722,532	)		(7,878,412	)
Net loss attributable to noncontrolling interest		(16,482	)		(17,087	)		(32,704	)		(32,927	)
Net loss attributable to CareView Communications, Inc.	$	(3,917,745	)	$	(3,692,784	)	$	(7,689,828	)	$	(7,845,485	)
Net loss per share attributable to CareView Communications, Inc., basic and diluted	$	(0.03	)	$	(0.03	)	$	(0.06	)	$	(0.06	)
Weighted average number of common shares outstanding, basic and diluted		139,380,748			138,960,678			139,380,748			138,857,611

4

CAREVIEW COMMUNICATIONS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT

FOR THE PERIOD FROM JANUARY 1, 2015 TO JUNE 30, 2015

(Unaudited)

					Additional
	Common Stock				Paid in		Accumulated			Noncontrolling
	Shares		Amount		Capital		Deficit			Interest			Total
Balance, January 1, 2015		139,380,748	$	139,381	$	76,502,913	$	(91,510,720	)	$	(436,609	)	$	(15,305,035	)
Stock options granted as compensation		—		—		410,033		—			—			410,033
Warrants issued in connection with the senior secured convertible notes		—		—		1,471,105		—			—			1,471,105
Warrants issued in connection with the credit facility		—		—		1,257,778		—			—			1,257,778
Beneficial conversion features for senior secured convertible notes		—		—		928,256		—			—			928,256
Net loss		—		—		—		(7,689,828	)		(32,704	)		(7,722,532	)
Balance, June 30, 2015		139,380,748	$	139,381	$	80,570,085	$	(99,200,548	)	$	(469,313	)	$	(18,960,395	)

5

CAREVIEW COMMUNICATIONS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE SIX MONTHS ENDED JUNE 30, 2015 AND 2014

(Unaudited)

	Six Months ended
	June 30, 2015			June 30, 2014
CASH FLOWS FROM OPERATING ACTIVITES
Net loss	$	(7,722,532	)	$	(7,878,412	)
Adjustments to reconcile net loss to net cash flows used in operating activities:
Depreciation		838,300			792,540
Provision for doubtful accounts		5,588			—
Amortization of debt discount		1,110,863			1,064,250
Amortization of installation costs		168,607			212,186
Amortization of intangible assets		19,852			14,168
Amortization of prepaid expense		15,915			—
Amortization of deferred debt issuance costs		2,431			284,692
Interest incurred and paid in kind		3,089,342			2,458,994
Stock based compensation related to options granted		410,033			341,677
Change in fair value of warrant liability		12,954			577,341
Loss on disposal of fixed assets		43,740			—
Changes in operating assets and liabilities:
Accounts receivable		(215,176	)		(140,447	)
Other current assets		(73,306	)		(66,596	)
Other assets		(747,283	)		124,928
Accounts payable		266,512			(195,610	)
Accrued expenses and other current liabilities		363,605			102,796
Other liabilities		—			(8,607	)
Net cash flows used in operating activities		(2,410,555	)		(2,316,100	)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property and equipment		(580,053	)		(308,465	)
Payment for deferred installation costs		(159,069	)		(242,566	)
Patent and trademark costs		(52,527	)		(9,458	)
Software and website costs		—			(6,349	)
Net cash flows used in investing activities		(791,649	)		(566,838	)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from notes and loans payable, net		5,901,445			5,000,000
Repayment of notes and loans payable		—			(1,850	)
Net cash flows provided by financing activities		5,901,445			4,998,150
Increase in cash		2,699,241			2,115,212
Cash, beginning of period		2,546,262			4,125,180
Cash, end of period	$	5,245,503		$	6,240,392
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid for interest	$	10,170		$	70,261
Cash paid for income taxes	$	—		$	—
SUPPLEMENTAL SCHEDULE OF NON-CASH FINANCING ACTIVITIES:
Beneficial conversion features for senior secured convertible notes	$	928,256		$	1,442,385
Warrants issued in connection with the credit facility	$	1,257,778		$	—
Warrants issued in connection with the senior secured convertible notes	$	1,471,105		$	1,146,732

6

CAREVIEW COMMUNICATIONS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 – BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

Interim Financial Statements

The accompanying unaudited interim condensed consolidated financial statements of CareView Communications, Inc. (“CareView”, the “Company”, “we”, “us” or “our”) have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, such financial statements include all adjustments (consisting solely of normal recurring adjustments) necessary for the fair statement of the financial information included herein in accordance with GAAP and the rules and regulations of the Securities and Exchange Commission (the “SEC”). The balance sheet at December 31, 2014 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by GAAP for complete financial statements. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the period. Actual results could differ from those estimates. Results of operations for interim periods are not necessarily indicative of results for the full year. The accompanying condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2014 as filed with the SEC on March 31, 2015.

Fair Value of Financial Instruments

Our financial instruments consist primarily of receivables, accounts payable, accrued expenses and short- and long-term debt. The carrying amount of receivables, accounts payable and accrued expenses approximates our fair value because of the short-term maturity of such instruments. We have elected not to carry our debt instruments at fair value. The carrying amount of our debt approximates fair value. Interest rates that are currently available to us for issuance of short- and long-term debt with similar terms and remaining maturities are used to estimate the fair value of the our short- and long-term debt and would be considered Level 3 inputs under the fair value hierarchy.

We have categorized our assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy in accordance with GAAP. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3).

Assets and liabilities recorded in the condensed consolidated balance sheets at fair value are categorized based on a hierarchy of inputs, as follows:

Level 1 -	Unadjusted quoted prices in active markets for identical assets or liabilities.
Level 2 -	Quoted prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument.
Level 3 -	Unobservable inputs for the asset or liability.

The Company’s financial assets and liabilities recorded at fair value on a recurring basis include the fair value of warrant liability as detailed below. The fair value of this warrant liability is included in long-term liabilities on the accompanying condensed consolidated financial statements.

7

CAREVIEW COMMUNICATIONS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 – BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS (Continued)

Fair Value of Financial Instruments (continued)

The following table provides the financial assets and liabilities reported at fair value and measured on a recurring basis:

Description	Assets/   (Liabilities)   Measured at Fair Value			Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Other Unobservable Inputs (Level3)
Fair value of warrant liability	$	(314,818	)	$	—	$	—	$	(314,818	)

The following table provides a summary of changes in fair value associated with the Level 3 liabilities for the six months ended June 30, 2015:

	Fair Value Measurements Using Significant Unobservable Inputs (Level3)
Balance at January 1, 2015	$	(301,864	)
Issuances of derivative liabilities		—
Change in fair value of warrant liability		(12,954	)
Transfers in and/out of Level 3		—
Ending balance at June 30, 2015	$	(314,818	)

The above table of Level 3 liabilities begins with the prior period balance and adjusts the balance for changes that occurred during the current period. The ending balance of the Level 3 securities presented above represent our best estimates and may not be substantiated by comparisons to independent markets and, in many cases, could not be realized in immediate settlement of the instruments.

Earnings Per Share

We calculate earnings per share (“EPS”) in accordance with GAAP, which requires the computation and disclosure of two EPS amounts, basic and diluted. Basic EPS is computed based on the weighted average number of shares of common stock outstanding during the period. Diluted EPS is computed based on the weighted average number of common shares outstanding plus all potentially dilutive common shares outstanding during the period under the treasury stock method. Such potential dilutive common shares consist of stock options, warrants and convertible debt. Potential common shares totaling 110,516,873 and 91,270,341 at June 30, 2015 and 2014, respectively, have been excluded from the diluted earnings per share calculation as they are anti-dilutive due to our reported net loss.

8

CAREVIEW COMMUNICATIONS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 – BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS (Continued)

Recently Issued and Newly Adopted Accounting Pronouncements

In April 2015, the Financial Accounting Standards Board (“FASB”), issued Accounting Standards Update (“ASU”) No. 2015-03, Interest-Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs. ASU 2015-03 requires that debt issuance costs be reported in the balance sheet as a direct deduction from the face amount of the related liability, consistent with the presentation of debt discounts and further requires the amortization of debt issuance cost to be reported as interest expense. Similarly, debt issuance costs and any discount or premium are considered in the aggregate when determining the effective interest rate of the debt. ASU 2015-03 is effective for fiscal years beginning after December 15, 2015 and interim periods within those fiscal years. Early adoption is permitted for annual or interim reporting periods for which the financial statements have not previously been issued. Management has opted for early adoption of ASU 2015-03 and there was no material effect on the consolidated financial statements upon adoption.

There have been no material changes to our significant accounting policies as summarized in NOTE 2 of our Annual Report on Form 10-K for the year ended December 31, 2014. We do not expect that the adoption of any recent accounting pronouncements will have a material impact on our accompanying condensed consolidated financial statements.

Reclassifications

Certain 2014 amounts have been reclassified to conform to current year presentation.

NOTE 2 – LIQUIDITY AND MANAGEMENT’S PLAN

Our cash position at June 30, 2015 was approximately $5,246,000.

Pursuant to the terms of a Note and Warrant Purchase Agreement dated April 21, 2011 (as subsequently amended) with HealthCor Partners Fund, LP and HealthCor Hybrid Offshore Master Fund, LP (“HealthCor”) we are required to maintain a minimum cash balance $2,000,000 (see NOTE 11 for further details), and we are in compliance with the minimum cash balance as of the date of this filing.

Our continued successful operation is dependent upon us achieving positive cash flow through operations while maintaining adequate liquidity. We expect that the cash on hand, as well as our existing and projected cash flow from billable contracts, will enable us to continue to operate for the next twelve month period. We believe that our sales and marketing plan to attract new business and our ongoing deployment and installation of units under existing hospital agreements, will meet our near-term cash needs and will help us achieve future operating profitability.

At present, we have sufficient inventory to install and service a select number of large customers, but eventually we will need to address additional capital requirements. To that end, on June 26, 2015, we entered into a Credit Agreement with PLD Biopharma, Inc., as administrative agent and lender (“the Lender”), (the “PDL Credit Agreement”) pursuant to which the Lender made available to us up to $40 million in two tranches of $20 million each, with each tranche contingent upon us meeting certain milestones (see NOTE 12 for further details). No funds were available on the PDL Credit Agreement at June 30, 2015.

9

CAREVIEW COMMUNICATIONS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 3 – STOCKHOLDERS’ EQUITY

Warrants to Purchase Common Stock of the Company

We use the Black-Scholes-Merton option pricing model (“Black-Scholes Model”) to determine the fair value of warrants to purchase our Common Stock (the “Warrant(s)”) (except certain Warrants issued to HealthCor and Warrants issued pursuant to the terms our March 2013 private placement (the “Private Placement Warrants”). The Black-Scholes Model is an acceptable model in accordance with GAAP. The Black-Scholes Model requires the use of a number of assumptions including volatility of the stock price, risk-free interest rate, and the estimated term of the Warrant. Estimated volatility is a measure of the amount by which our stock price is expected to fluctuate each year during the expected life of the award. Our estimated volatility is an average of the historical volatility of our stock prices (and that of peer entities whose stock prices were publicly available). Our calculation of estimated volatility is based on historical stock prices over a period equal to the expected life of the awards. Where appropriate we used the historical volatility of peer entities due to the lack of sufficient historical data of our stock price during 2007-2009. The risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the term of the Warrant and is calculated by using the average daily historical stock prices through the day preceding the grant date.

The fair value of the above mentioned Warrants issued to HealthCor and the Private Placement Warrants was computed using the Binomial Lattice model, incorporating transaction details such as the price of our Common Stock, contractual terms, maturity and risk free rates, as well as assumptions about future financings, volatility, and holder behavior. Due to the down round provisions associated with the exercise price of these Warrants, we determined that the Binomial Lattice model was the most appropriate model for valuing these instruments.

Warrant Activity during the Six Months Ended June 30, 2015

On June 26, 2015, in conjunction with the PLD Credit Agreement, we issued a warrant to purchase 4,444,445 shares of our Common Stock, subject to adjustment as described therein (the “PDL Warrant”). The PDL Warrant has an exercise price of $0.45, a fair value of $1,257,778, and expires on June 26, 2025 (see NOTE 12 for further details).

On February 17, 2015, we entered into a Fifth Amendment to the Note and Warrant Purchase Agreement with HealthCor and certain other investors and agreed to sell and issue (i) additional notes in the initial aggregate principal amount of $6,000,000, with a conversion price per share equal to $0.52 (subject to adjustment for standard anti-dilution provisions) and (ii) additional Warrants for an aggregate of up to 3,692,307 shares of our Common Stock at an exercise price per share equal to $0.52 (subject to adjustment for standard anti-dilution provisions) (the “Fifth Amendment Warrants”). The fair value of the convertible debt and the Fifth Amendment Warrants was determined to be $7,336,615, resulting in a relative fair value of $1,093,105 for the Fifth Amendment Warrants on the date of grant (see NOTE 11 for further details)

On March 31, 2015, we issued HealthCor a Warrant for up to an aggregate of 1,000,000 shares of our Common Stock in consideration for certain prior waivers of the minimum cash balance requirement in the Purchase Agreement. This Warrant has an exercise price of $0.53 per share, expires on March 31, 2025 and has a fair value of $378,000 (see NOTE 11 for further details).

As of December 31, 2014, we recorded a warrant liability of $301,864 in our consolidated financial statements. At June 30, 2015, the Private Placement Warrants were re-valued with a fair value determination of $314,818, resulting in a difference of $12,954, which was included as change in fair value of warrant liability in other income and expense in the accompanying condensed consolidated financial statements.

10

CAREVIEW COMMUNICATIONS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 3 – STOCKHOLDERS’ EQUITY (Continued)

Warrants to Purchase Common Stock of the Company (continued)

Warrant Activity during the Six Months Ended June 30, 2015 (continued)

During the six months ended June 30, 2015, warrants to purchase an aggregate of 2,892,686 shares of our Common Stock expired.

Warrant Activity during the Six Months Ended June 30, 2014

On January 16, 2014, we entered into a Fourth Amendment to the Note and Warrant Purchase Agreement with HealthCor and agreed to sell and issue (i) additional notes in the initial aggregate principal amount of $5,000,000, with a conversion price per share equal to $0.40 (subject to adjustment for standard anti-dilution provisions) and (ii) additional Warrants for an aggregate of up to 4,000,000 shares of our Common Stock at an exercise price per share equal to $0.40 (subject to adjustment for standard anti-dilution provisions) (the “Fourth Amendment Warrants”). The fair value of the convertible debt and the Fourth Amendment Warrants was determined to be $6,488,000, resulting in a relative fair value of $1,146,732 for the Fourth Amendment Warrants on the date of grant.

As of December 31, 2013, we recorded a warrant liability of $370,865 in our condensed consolidated financial statements. At June 30, 2014, the Private Placement Warrants were re-valued with a fair value determination of $948,206 and the difference of $577,341 was included as change in fair value of warrant liability in other income and expense in the accompanying condensed consolidated financial statements.

Options to Purchase Common Stock of the Company

On February 25, 2015, we established the CareView Communications, Inc. 2015 Stock Option Plan (the “2015 Plan”) pursuant to which 5,000,000 shares of Common Stock was reserved for issuance upon the exercise of options (“2015 Plan Option(s)”). The 2015 Plan was designed to serve as an incentive for retaining our qualified and competent key employees, officers and directors. The 2015 Plan Options vest over three years and have an exercise period of ten years from the date of issuance.

During the six months ended June 30, 2015, we granted options to purchase 1,815,000 shares of our Common Stock (the ‘‘Option(s)’’) to certain employees and members of our board of directors. We granted 1,300,000 Options to certain employees and members of our board of directors during the six months ended June 30, 2014. During those same six month periods, 77,837 and 15,000 Options, respectively, were canceled and 6,261,308 and 41,666 Options, respectively, expired.

11

CAREVIEW COMMUNICATIONS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 

NOTE 3 – STOCKHOLDERS’ EQUITY (Continued)

Options to Purchase Common Stock of the Company (continued)

A summary of our stock option activity and related information follows:

	Number of Shares Under Options			Weighted Average Exercise Price		Weighted   Average   Remaining   Contractual   Life		Aggregate Intrinsic Value
Balance at December 31, 2014		14,273,810		$	0.58		6.3	$	—
Granted		1,815,000		$	0.53		9.7	$	—
Expired		(6,261,308	)
Canceled		(77,837	)
Balance at June 30, 2015		9,749,665		$	0.61		7.9	$	—
Vested and Exercisable at June 30, 2015		3,940,489		$	0.74		6.7	$	—

The valuation methodology used to determine the fair value of the Options issued was the Black-Scholes Model.

The assumptions used in the Black-Scholes Model are set forth in the table below.

	Six Months   Ended June 30, 2015			Year Ended   December 31, 2014
Risk-free interest rate		1.41-1.47	%		1.59-1.83	%
Volatility		71.30-71.86	%		72.82-75.42	%
Expected life in years		6			6
Dividend yield		0.00	%		0.00	%

The risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the expected term of the Option and is calculated by using the average daily historical stock prices through the day preceding the grant date. Estimated volatility is a measure of the amount by which our stock price is expected to fluctuate each year during the expected life of the award. Our estimated volatility is an average of the historical volatility of our stock prices. Our calculation of estimated volatility is based on historical stock prices over a period equal to the expected life of the awards.

Share-based compensation expense for Options charged to our operating results for the six months ended June 30, 2015 and 2014 ($410,034 and $341,677, respectively) is based on awards vested. The estimate of forfeitures are to be recorded at the time of grant and revised in subsequent periods if actual forfeitures differ from the estimates. We have not included an adjustment to our stock based compensation expense based on the nominal amount of the historical forfeiture rate. We do, however, revise our stock based compensation expense based on actual forfeitures during each reporting period.

At June 30, 2015, total unrecognized estimated compensation expense related to non-vested Options granted prior to that date was approximately 1,469,000, which is expected to be recognized over a weighted-average period of 1.9 years. No tax benefit was realized due to a continued pattern of operating losses.

12

CAREVIEW COMMUNICATIONS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 

NOTE 4 – OTHER CURRENT ASSETS

Other current assets consist of the following:

	June 30, 2015		December 31, 2014
Prepaid expenses	$	350,087	$	254,998
Other current assets		129		21,912
TOTAL OTHER CURRENT ASSETS	$	350,216	$	276,910

NOTE 5 – PROPERTY AND EQUIPMENT

Property and equipment consist of the following:

	June 30, 2015			December 31, 2014
Network equipment	$	11,139,319		$	10,753,542
Office equipment		176,126			160,890
Vehicles		164,501			132,797
Test equipment		115,540			87,059
Furniture		75,673			75,673
Warehouse equipment		8,440			6,867
Leasehold improvements		13,348			5,121
		11,692,947			11,221,949
Less: accumulated depreciation		(6,650,142	)		(5,877,157	)
TOTAL PROPERTY AND EQUIPMENT	$	5,042,805		$	5,344,792

Depreciation expense for the six months ended June 30, 2015 and 2014 was $838,300 and $792,540, respectively.

At June 30, 2015, some portion of our network equipment is in excess of current requirements based on the recent level of installations. We have developed a program to deploy assets over the near term and believe no impairment exists at June 30, 2015. No estimate can be made of a range of amounts of loss that are reasonably possible should we not be successful.

NOTE 6 – OTHER ASSETS

Intangible assets consist of the following:

	June 30, 2015
	Cost		Accumulated Amortization		Net
Patents and trademarks	$	323,669	$	42,354	$	281,315
Other intangible assets		51,464		38,821		12,643
TOTAL INTANGIBLE ASSETS	$	375,133	$	81,175	$	293,958

	December 31, 2014
	Cost		Accumulated Amortization		Net
Patents and trademarks	$	271,142	$	26,157	$	244,985
Other intangible assets		51,464		35,166		16,298
TOTAL INTANGIBLE ASSETS	$	322,606	$	61,323	$	261,283

13

CAREVIEW COMMUNICATIONS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 

NOTE 6 – OTHER ASSETS (Continued)

Other assets consist of the following:

	June 30, 2015
	Cost		Accumulated Amortization		Net
Deferred debt issuance costs	$	1,257,778	$	2,431	$	1,255,347
Prepaid financing costs		1,133,480		15,915		1,117,565
Deferred installation costs		1,616,167		1,034,254		581,913
Prepaid license fee		249,999		62,841		187,158
Security deposit		46,124		—		46,124
TOTAL OTHER ASSETS	$	4,303,548	$	1,115,441	$	3,188,107

	December 31, 2014
	Cost		Accumulated Amortization		Net
Deferred installation costs	$	1,457,098	$	865,647	$	591,451
Prepaid license fee		249,999		54,644		195,355
Security deposit		46,124		—		46,124
TOTAL OTHER ASSETS	$	1,753,221	$	920,291	$	832,930

NOTE 7 – OTHER CURRENT LIABILITIES

Other current liabilities consist of the following:

	June 30, 2015		December 31, 2014
Accrued issuance costs	$	550,000	$	—
Accrued taxes		201,270		145,183
Accrued paid time off		89,359		87,319
Accrued travel and entertainment		79,097		35,000
Accrued insurance		75,832		—
Allowance for system removal		61,121		277,000
Accrued professional services		30,400		204,675
Other accrued liabilities		34,180		42,107
TOTAL OTHER CURRENT LIABILITIES	$	1,121,259	$	791,284

NOTE 8 – INCOME TAXES

Deferred income tax assets and liabilities are determined based upon differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. We do not expect to pay any significant federal or state income tax for 2015 as a result of the losses recorded during the six months ended June 30, 2015 and the additional losses expected for the remainder of 2015 and net operating loss carry forwards from prior years. Accounting standards require the consideration of a valuation allowance for deferred tax assets if it is “more likely than not” that some component or all of the benefits of deferred tax assets will not be realized. As of June 30, 2015, we maintained a full valuation allowance for all deferred tax assets. Based on these requirements, no provision or benefit for income taxes has been recorded. There were no recorded unrecognized tax benefits at the end of the reporting period.

14

CAREVIEW COMMUNICATIONS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 

NOTE 9 – JOINT VENTURE AGREEMENT

On November 16, 2009, we entered into a Master Investment Agreement (the “Rockwell Agreement”) with Rockwell Holdings I, LLC, a Wisconsin limited liability (“Rockwell”). Under the terms of the Rockwell Agreement, we used funds from Rockwell to fully implement the CareView System™ in Hillcrest Medical Center in Tulsa, Oklahoma (“Hillcrest”) and Saline Memorial Hospital in Benton, Arkansas (“Saline”) (the “Project Hospital(s)”). CareView-Hillcrest, LLC and CareView-Saline, LLC were created as the operating entities for the Project Hospitals under the Rockwell Agreement (the “Project LLC(s) “).

Rockwell and the Company own 50% of each Project LLC. We contributed our intellectual property rights and hospital contract with each Project Hospital and Rockwell contributed cash to be used for the purchase of equipment for the Project LLCs. Rockwell provided $1,151,205 as the initial funding, $575,603 was provided under promissory notes (the “Project Notes”) and $575,602 was provided under an investment interest (“Rockwell’s Preferential Return”). We classified Rockwell’s Preferential Return as a liability since it represents an unconditional obligation by us and is recorded in mandatorily redeemable equity in joint venture on the accompanying consolidated financial statements. The Project Notes and Rockwell’s Preferential Returns both earn interest at the rate of ten percent (10%) and are secured by a security interest in all of the equipment in the Project Hospitals, intellectual property rights, and the Project Hospital Contract

In accordance with GAAP, we determined the Project LLCs are VIEs based on the fact that the total equity investment at risk was not sufficient to finance the entities activities without additional financial support. We consolidate the Project LLCs as we have the power to direct the activities and an obligation to absorb losses of the VIEs. We have no contractual liability to Rockwell with respect to the repayment obligations of the Project LLCs.

As additional consideration to Rockwell for providing the funding, we granted Rockwell Warrants to purchase 1,151,206 shares of our Common Stock on the date of the Rockwell Agreement, and using the Black-Scholes Model valued the Warrants at $1,124,728 (the “Project Warrant”). The Project Warrant is classified as equity and is included in additional paid-in-capital on the accompanying consolidated financial statements. We allocated the proceeds to the Project Warrant, the Project Notes and Preferential Returns based on the relative fair value. The originally recorded debt discount of $636,752 was amortized over the expected life of the debt and was fully amortized as of March 31, 2013.

Hillcrest notified us of its desire to terminate its hospital agreement effective January 27, 2012. This termination resulted in the loss of monthly revenue totaling approximately $20,000, which revenue was used to make payments on our indebtedness to Rockwell. To date, we have incurred system removal costs of approximately $3,000 for removing our equipment from the hospital premises. We currently have approximately 100 units remaining on site at Hillcrest. Included in other current liabilities in the accompanying consolidated financial statements is an allowance for system removal totaling $10,250 to reserve for the removal of the remaining units.

As of June 30, 2015, the Project LLCs’ indebtedness to Rockwell, including principal and interest totaled approximately $1,108,000. On March 18, 2014, the Project Notes and Rockwell’s Preferential Returns, previously due on June 30, 2014 (the “June 2014 extensions”), were extended to June 30, 2015. On February 19, 2015, the Project Notes and Rockwell’s Preferential Returns due dates were extended to June 30, 2016. In conjunction with an August 2013 extension of the due dates of the Project Notes and Rockwell’s Preferential Returns to December 31, 2013, the expiration date of the Project Warrant was also extended from November 16, 2014 to November 16, 2015. All other provisions of the Project Warrant remained unchanged. The Project Warrant were amended and revalued in August 2013 resulting in a $25,327 increase in fair value, which has been recorded as non-cash costs included in general and administration expense in the accompanying consolidated financial statements. CareView, as 50% owner of the LLCs, is currently negotiating with Rockwell to settle the debt of the LLCs through the issuance of shares of CareView’s Common Stock. Although CareView anticipates that this settlement will be forthcoming in the near future, CareView and the LLCs can give no assurances that a settlement will be negotiated, or if negotiated and settled, that it will be through the issuance of CareView’s Common Stock.

15

CAREVIEW COMMUNICATIONS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 

NOTE 10 – VARIABLE INTEREST ENTITIES

The Company consolidates VIEs of which it is the primary beneficiary. The liabilities recognized as a result of consolidating these VIEs do not necessarily represent additional claims on our general assets; rather, they represent claims against the specific assets of the consolidated VIEs. Conversely, assets recognized as a result of consolidating these VIEs do not represent additional assets that could be used to satisfy claims against our general assets.

The total consolidated VIE assets and liabilities reflected on our consolidated balance sheets at June 30, 2015 and December 31, 2014 are as follows:

	June 30, 2015		December 31, 2014
Assets
Cash	$	372	$	2,770
Receivables		4,731		2,365
Total current assets		5,103		5,135
Property, net		24,289		46,762
Total assets	$	29,392	$	51,897
Liabilities
Accounts payable	$	127,962	$	122,558
Accrued interest		225,226		191,596
Other current liabilities		25,101		24,889
Notes payable-LT		441,594		441,594
Mandatorily redeemable interest-LT		441,594		441,594
Total liabilities	$	1,261,477	$	1,222,231

16

CAREVIEW COMMUNICATIONS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS  

NOTE 10 – VARIABLE INTEREST ENTITIES (Continued)

The financial performance of the consolidated VIEs reflected on our condensed consolidated statements of operations for the six months ended June 30, 2015 and 2014 is as follows:

	June 30,
	2015			2014
Revenue	$	14,194		$	14,259
Network operations expense		8,328			8,337
General and administrative expense (cost recovery)		1,485			1,473
Depreciation		24,464			25,264
Total operating costs		34,277			35,074
Operating loss		(20,083	)		(20,815	)
Other expense		(45,296	)		(45,039	)
Loss before taxes		(65,379	)		(65,854	)
Provision for taxes		—			—
Net loss		(65,379	)		(65,854	)
Net loss attributable to noncontrolling interest		(32,689	)		(32,927	)
Net loss attributable to CareView Communications, Inc.	$	(32,689	)	$	(32,927	)

NOTE 11 – AGREEMENT WITH HEALTHCOR

On April 21, 2011, we entered into a Note and Warrant Purchase Agreement (as subsequently amended) (the “HealthCor Purchase Agreement”) with HealthCor. Pursuant to the HealthCor Purchase Agreement, we sold Senior Secured Convertible Notes to HealthCor in the principal amount of $9,316,000 and $10,684,000, respectively (collectively the “2011 HealthCor Notes”). The 2011 HealthCor Notes have a maturity date of April 20, 2021. We also issued Warrants to HealthCor for the purchase of an aggregate of up to 5,488,456 and 6,294,403 shares, respectively, of our Common Stock at an exercise price of $1.40 per share (collectively the “2011 HealthCor Warrants”).

So long as no event of default has occurred, the outstanding principal balances of the 2011 HealthCor Notes accrue interest from April 21, 2011 through April 20, 2016 (the “First Five Year Note Period”) at the rate of 12.5% per annum, compounding quarterly and shall be added to the outstanding principal balances of the 2011 HealthCor Notes on the last day of each calendar quarter. Interest accruing from April 21, 2016 through April 20, 2021 (the “Second Five Year Note Period”) at a rate of 10% per annum, compounding quarterly, may be paid quarterly in arrears in cash or, at our option, such interest may be added to the outstanding principal balances of the 2011 HealthCor Notes on the last day of each calendar.

From the date any event of default occurs, the interest rate, then applicable, shall be increased by five percent (5%) per annum. HealthCor has the right, upon an event of default, to declare due and payable any unpaid principal amount of the 2011 HealthCor Notes then outstanding, plus previously accrued but unpaid interest and charges, together with the interest then scheduled to accrue (calculated at the default rate described in the immediately preceding sentence) through the end of the First Five Year Note Period or the Second Five Year Note Period, as applicable.

At any time after April 21, 2011, HealthCor is entitled to convert any portion of the outstanding and unpaid accrued interest on and principal balances of the 2011 HealthCor Notes into fully paid and non-assessable shares of our Common Stock at a conversion rate of $1.25 per share, subject to adjustment in accordance with anti-dilution provisions set forth in the 2011 HealthCor Notes. As of June 30, 2015, the underlying shares of our Common Stock related to the 2011 HealthCor Notes totaled approximately 26,808,000.

17

CAREVIEW COMMUNICATIONS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 

NOTE 11 – AGREEMENT WITH HEALTHCOR (Continued)

On January 31, 2012, we entered into the Second Amendment to the HealthCor Purchase Agreement with HealthCor (the “Second Amendment”) amending the HealthCor Purchase Agreement, and sold Senior Secured Convertible Notes to HealthCor in the principal amounts of $2,329,000 and $2,671,000, respectively (collectively the “2012 HealthCor Notes”). As provided by the Second Amendment, the 2012 HealthCor Notes are in substantially the same form as the 2011 HealthCor Notes, with changes to the “Issuance Date,” “Maturity Date,” “First Five Year Note Period” and other terms to take into account the timing of the issuance of the 2012 HealthCor Notes. The 2012 HealthCor Notes have a maturity date of January 30, 2022. In addition, the provisions regarding interest payments, interest acceleration, optional conversion, negative covenants, and events of default, preemptive rights and registration rights are the same as those of the 2011 HealthCor Notes. At any time after January 30, 2012, HealthCor is entitled to convert any portion of the outstanding and unpaid accrued interest on and principal balances of the 2012 HealthCor Notes into fully paid and non-assessable shares of our Common Stock at a conversion rate of $1.25 per share, subject to adjustment in accordance with anti-dilution provisions set forth in the 2012 HealthCor Notes. As of June 30, 2015, the underlying shares of our Common Stock related to the 2012 HealthCor Notes totaled approximately 6,090,000.

On August 20, 2013, we entered into a Third Amendment to the HealthCor Purchase Agreement with HealthCor (the “Third Amendment”) to redefine our minimum cash balance requirements. Previously we were required to maintain a minimum cash balance of $5,000,000 and should we drop below that balance, it triggered a default. The Third Amendment allowed for a reduced minimum cash period, as defined in the HealthCor Purchase Agreement, which allowed us to drop below $5,000,000, but not below $4,000,000. All other terms and conditions of the HealthCor Purchase Agreement, including all amendments thereto, remain the same. Upon entering the reduced minimum cash period (which occurred on October 7, 2013), we had 120 days to return our minimum cash balance to the original $5,000,000. On January 16, 2014, we increased our cash balance to in excess of the original $5,000,000 minimum allowable balance.

On January 16, 2014, we entered into a Fourth Amendment to the HealthCor Purchase Agreement with HealthCor (the “Fourth Amendment”) and sold Senior Secured Convertible Notes to HealthCor in the principal amounts of $2,329,000 and $2,671,000 (collectively the ‘‘2014 HealthCor Notes’’). As provided by the Fourth Amendment, the 2014 HealthCor Notes are in substantially the same form as the 2011 HealthCor Notes, with changes to the “Issuance Date,” “Maturity Date,” “First Five Year Note Period” and other terms to take into account the timing of the issuance of the 2014 HealthCor Notes. The 2014 HealthCor Notes have a maturity date of January 15, 2024. In addition, the provisions regarding interest payments, interest acceleration, optional conversion, negative covenants, and events of default, preemptive rights and registration rights are the same as those of the 2011 HealthCor Notes. At any time after January 16, 2014, HealthCor is entitled to convert any portion of the outstanding and unpaid accrued interest on and principal balances of the 2014 HealthCor Notes into fully paid and non-assessable shares of our Common Stock at a conversion rate of $0.40 per share, subject to adjustment in accordance with anti-dilution provisions set forth in the 2014 HealthCor Notes. Additionally we issued Warrants to HealthCor for the purchase of an aggregate of up to 4,000,000 shares of our Common Stock at an exercise price of $0.40 per share (collectively the “2014 HealthCor Warrants”). As of June 30, 2015, the underlying shares of our Common Stock related to the 2014 HealthCor Notes totaled approximately 14,954,000.

18

CAREVIEW COMMUNICATIONS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 

NOTE 11 – AGREEMENT WITH HEALTHCOR (Continued)

On December 4, 2014, we entered into a Fifth Amendment to the HealthCor Purchase Agreement (the “Fifth Amendment”) with HealthCor and certain additional investors (such additional investors, the “New Investors” and, collectively with HealthCor Partners Fund, LP, the “Investors”) and agreed to sell and issue (i) additional notes in the initial aggregate principal amount of $6,000,000,with a conversion price per share of $0.52 (subject to adjustment as described therein) (the “Fifth Amendment Notes”) and (ii) additional Warrants for an aggregate of up to 3,692,308 shares of our Common Stock at an exercise price per share of $0.52 (subject to adjustment as described therein) (the “Fifth Amendment Warrants”). As provided by the Fifth Amendment, the Fifth Amendment Notes are in substantially the same form as the 2011 HealthCor Notes, with changes to the “Issuance Date,” “Maturity Date,” “First Five Year Note Period” and other terms to take into account the timing of the issuance of the Fifth Amendment Notes. The 2014 HealthCor Notes have a maturity date of February 16, 2025. In addition, the provisions regarding interest payments, interest acceleration, optional conversion, negative covenants, and events of default, preemptive rights and registration rights are the same as those of the 2011 HealthCor Notes. The New Investors are composed of all but one of our current directors and one of our officers. On February 17, 2015, the Company and the Investors closed on the transactions contemplated by the Fifth Amendment. In connection with this closing, the Company and the Investors entered into an Amended and Restated Pledge and Security Agreement (the “Amended Security Agreement”), amending and restating that certain Pledge and Security Agreement dated as of April 20, 2011, and an Amended and Restated Intellectual Property Security Agreement (the “Amended IP Security Agreement”), amending and restating that certain Intellectual Property Security Agreement dated as of April 20, 2011. As of June 30, 2015, the underlying shares of our Common Stock related to the Fifth Amendment Notes totaled approximately 2,012,000 to HealthCor and 10,061,000to the New Investors.

On March 31, 2015, we entered into the Sixth Amendment to the HealthCor Purchase Agreement (the “Sixth Amendment”) pursuant to which, among other things, (i) the requirement to maintain a minimum cash balance of $5,000,000 was reduced to a minimum cash balance of $2,000,000 and (ii) the amendment provision was revised to permit the HealthCor Purchase Agreement to be amended by the Company and the holders of the majority of the Common Stock underlying the outstanding notes and warrants to purchase shares of our Common Stock sold pursuant to the HealthCor Purchase Agreement. On March 31, 2015, we also issued a warrant to HealthCor to purchase up to an aggregate of 1,000,000 shares of our Common Stock in consideration for certain prior waivers of the minimum cash balance requirement in the HealthCor Purchase Agreement (the “Sixth Amendment Warrant”). The Sixth Amendment Warrant has an exercise price per share of $0.53 (subject to adjustment as described therein) and an expiration date of March 31, 2025.

On June 26, 2015, we (i) entered into a Seventh Amendment to the HealthCor Purchase Agreement (the “Seventh Amendment”) pursuant to which the HealthCor Purchase Agreement was amended to permit the Company to enter into and perform its obligations under the Credit Agreement entered into with PDL BioPharma, Inc., as administrative agent and lender (the “Lender”) (the “PDL Credit Agreement”); (ii) executed an Amendment to the Registration Rights Agreement between the Company and HealthCor dated April 21, 2011 (the “RR Agreement”) pursuant to which the RR Agreement was amended to make its priority of registration consistent with the Registration Rights Agreement executed by the Company and Lender (as detailed in NOTE 12); (iii) amended the 2011 HealthCor Notes to extend the maturity date, in the event that Tranche Two of the PDL Credit Agreement is funded, for such notes to 90 days after the earlier of the Tranche Two maturity date or repayment date, but not later than December 31, 2022, (iv) amended the 2012 HealthCor Notes, to set the maturity date at January 30, 2022 and, in the event that Tranche Two of the PDL Credit Agreement is funded, to extend such maturity date to 90 days after the earlier of the Tranche Two maturity date or repayment date, but later than December 31, 2022; and (v) amended each of the Senior Secured Convertible Notes issued under the HealthCor Purchase Agreement (the “HealthCor Notes”)to, among other things, subordinate the HealthCor Notes to the loans under the PDL Credit Agreement (as detailed in NOTE 12) and to increase certain event of default acceleration and payment thresholds.

19

CAREVIEW COMMUNICATIONS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 

NOTE 11 – AGREEMENT WITH HEALTHCOR (Continued)

Accounting Treatment

When issuing debt or equity securities convertible into common stock at a discount to the fair value of the common stock at the date the debt or equity financing is committed, a company is required to record a beneficial conversion feature (“BCF”) charge. We had three separate issuances of equity securities convertible into common stock that qualify under this accounting treatment, (i) the 2011 HealthCor Notes, (ii) the 2012 HealthCor Notes and (iii) the 2014 HealthCor Notes. Because the conversion option and the 2011 HealthCor Warrants on the 2011 HealthCor Notes were originally classified as a liability when issued and, subsequently reclassified to equity on December 31, 2011 when the 2011 HealthCor Notes were amended, only the accrued interest capitalized as payment in kind (‘‘PIK’’) since reclassification qualifies under this accounting treatment. The face amount of the 2012 and 2014 HealthCor Notes and all accrued PIK interest also qualify for this accounting treatment. During the three and six months ended June 30, 2015, we recorded a BCF of $471,268 and $928,255, respectively, and during the three and six months ended June 30, 2014, we recorded a BCF of $416,689 and $817,384, respectively. The BCF was recorded as a charge to debt discount and a credit to additional paid in capital, with the debt discount, using the effective interest method, amortized to interest expense over the term of the notes. As Warrants were issued with the 2014 HealthCor Notes and the Fifth Amendment Notes, the proceeds were allocated to the instruments based on relative fair value. The value allocated to the 2014 HealthCor Warrants and the Fifth Amendment Notes were $1,146,732 and $1,093,105, respectively, which were recorded as a debt discount with the credit to additional paid in capital. The discount associated with the 2014 HealthCor Warrants and the Fifth Amendment Notes is amortized to interest expense using the effective interest method.

We recorded an aggregate of $558,797 and $1,110,863 in interest expense for the three and six months ended June 30, 2015, respectively, and $535,833 and $1,064,251 in interest expense for the three and six months ended June 30, 2014, respectively, related to this discount. The carrying value of the debt with HealthCor at June 30, 2015 approximates fair value as the interest rates used are those currently available to us and would be considered level 3 inputs under the fair value hierarchy.

NOTE 12 – AGREEMENT WITH PDL BIOPHARMA, INC.

On June 26, 2015, we entered into a Credit Agreement with PDL BioPharma, Inc., as administrative agent and lender (“the Lender”) (the “PDL Credit Agreement”). Under the PDL Credit Agreement the Lender made available to us up to $40 million in two tranches of $20 million each.

In the event that a milestone relating to the placement of 9,000 billable units occurs on or before October 31, 2015, the Lender will fund us $20 million (“Tranche One”). In the event that additional milestones relating to (i) the placement of 27,750 billable units and (ii) the Company recording earnings before interest, tax, depreciation, and amortization (EBITDA) of not less than $7,000,000 on an annualized basis for the three calendar month period prior to the funding (on or before June 30, 2017), the Lender will fund us an additional $20 million (“Tranche Two” and, together with Tranche One, the “Loans”). Outstanding borrowings under Tranche One bear interest at the rate of 13.5% per annum, payable quarterly in arrears. Outstanding borrowings under Tranche Two bear interest at the rate of 13.0% per annum, payable quarterly in arrears.

Principal repayment under each of Tranche One and Tranche Two will commence on the ninth interest payment date. We may elect to pay a portion of the interest due in the form of additional loans during the first eight interest payment dates. Each tranche will mature on the fifth anniversary of the date borrowed. We may elect to prepay the Loans at any time without any premium or penalty, subject to certain conditions.

20

CAREVIEW COMMUNICATIONS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS  

NOTE 12 – AGREEMENT WITH PDL BIOPHARMA, INC. (Continued)

The obligations under the PDL Credit Agreement are secured by a pledge of substantially all of the assets of the Company and certain of its domestic subsidiaries. We executed a Subordination and Intercreditor Agreement (the “Subordination and Intercreditor Agreement”), with the Lender, HealthCor and the New Investors (as defined in NOTE 11) pursuant to which we granted first-priority liens on our pledged assets to the Lender and second-priority liens on such pledged assets to HealthCor and the New Investors.

The PDL Credit Agreement contains customary affirmative covenants for transactions of this type and other affirmative covenants agreed to by the Company and the Lender, including, among others, the provision of annual and quarterly reports, maintenance of property, insurance, compliance with laws and contractual obligations and payment of taxes. The PDL Credit Agreement contains customary negative covenants for transactions of this type and other negative covenants agreed to by the Company and the Lender, including, among others, restrictions on the incurrence of indebtedness, the granting of liens, making restricted payments and investments, entering into affiliate transactions and transferring assets. The PDL Credit Agreement also provides for a number of customary events of default, including payment, bankruptcy, covenant, representation and warranty and judgment defaults.

Contemporaneously with the execution of the PDL Credit Agreement, we issued to the Lender a warrant to purchase 4,444,445 shares of our Common Stock at an exercise price of $0.45 per share, subject to adjustment as described therein (the “PDL Warrant”). The PDL Warrant expires on June 26, 2025.

In addition, contemporaneously with the execution of the PDL Credit Agreement the Company and the Lender executed (i) a Registration Rights Agreement pursuant to which the Company agreed to provide the Lender with certain registration rights with respect to the shares of Common Stock issuable upon exercise of the PDL Warrant (the “PDL RRA”), (ii) a Guarantee and Collateral Agreement (the “Guarantee and Collateral Agreement”) pursuant to which certain of our subsidiaries guaranteed the performance of our obligations under the PDL Credit Agreement and granted the Lender a security interest in such subsidiaries’ tangible and intangible assets securing our performance of the same, and (iii) a Patent Security Agreement and a Trademark Security Agreement pursuant to which we granted the Lender a security interest in a certain subsidiary’s tangible and intangible assets securing the performance of our obligations under the PDL Credit Agreement.

Accounting Treatment

In connection with the Credit Agreement, we issued the PDL Warrant to the Lender. The fair value of the PDL Warrant at issuance was $1,257,778 and has been recorded as deferred issuance costs in the accompanying condensed consolidated financial statements. These costs are amortized to interest expense using the straight line method over the term of the Credit Agreement. Through June 30, 2015, $2,431 was amortized to interest expense. The PDL Warrant has not been exercised. We also incurred certain financing costs totaling $746,811 in the accompanying condensed consolidated financial statements. These costs have been recorded as deferred financing costs and are being amortized to interest expense over the term of the Credit Agreement. Through June 30, 2015, $1,464 has been amortized.

21

Item 2.    Management’s Discussion and Analysis of Financial Condition and Results of Operations

General

The following discussion and analysis provides information which our management believes to be relevant to an assessment and understanding of our results of operations and financial condition. This discussion should be read together with our financial statements and the notes to the financial statements, which are included in this Quarterly Report on Form 10-Q (the “Report”). This information should also be read in conjunction with the information contained in our Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on March 31, 2015, including the audited consolidated financial statements and notes included therein as of and for the year ended December 31, 2014. The reported results will not necessarily reflect future results of operations or financial condition.

Throughout this Annual Report on Form 10-K (the “Report”), the terms “we,” “us,” “our,” “CareView,” or “our Company” refers to CareView Communications, Inc., a Nevada corporation, and unless otherwise specified, includes our wholly owned subsidiaries, CareView Communications, Inc., a Texas corporation (“CareView-TX”) and CareView Operations, LLC, a Nevada limited liability company (“CareView Operations”) (collectively known as the “Company’s Subsidiaries”) and its LLCs, CareView-Hillcrest and CareView-Saline, determined to be variable interest entities (“VIEs”) in which the Company exercises control and is deemed the Primary Beneficiary (collectively known as the “Company’s LLCs”).

We maintain a website at www.care-view.com and our Common Stock trades on the OTCQB under the symbol “CRVW.’’

Company Overview

Our mission is to be the leading provider of products and on-demand application services for the healthcare industry, specializing in bedside video monitoring, software tools to improve hospital communications and operations, and patient education and entertainment packages. Our proprietary, high-speed data network system is the next generation of patient care monitoring that allows real-time bedside and point-of-care video monitoring designed to improve patient safety and overall hospital costs. The entertainment packages and patient education enhance the patient’s quality of stay. Reported results from CareView-driven hospitals prove that our products reduce falls, reduce the cost of sitter fees, increase patient satisfaction and reduce bed turnaround time to increase patient flow. For patients, we have a convenient in-room, entertainment package that includes high-speed Internet, access to first-run on-demand movies and visual connectivity to family and friends from anywhere in the world. For the hospital, we offer tools to provide superior patient care, peace of mind and customer service satisfaction.

Our CareView System^® suite of video monitoring, guest services and related applications connect patients, families and healthcare providers. Through the use of telecommunications technology and the Internet, our evolving products and on-demand services greatly increase the access to quality medical care and education for patients/consumers and healthcare professionals. We understand the importance of providing high quality patient care in a safe environment and believe in partnering with hospitals to improve the quality of patient care and safety by providing a system that monitors and records continuously. We are committed to providing an affordable video monitoring tool to improve the practice of nursing, create a better work environment and make the patient’s hospital stay more informative and satisfying. Our suite of products and services can simplify and streamline the task of preventing and managing patients’ falls, enhance patient safety, improve quality of care and reduce costs associated with bringing information technology directly to patients, families and healthcare providers. Our products and services can be used in all types of hospitals, nursing homes, adult living centers and selected outpatient care facilities domestically and internationally.

22

The CareView System secure video monitoring system connects the patient room to a touch-screen monitor at the nursing station, allowing nursing staff to maintain a level of visual contact with each patient. This configuration enhances the use of the nurse call system, reduces unnecessary steps to and from patient rooms, and the recording capability allows for a video record of all in-room activity during the length of the patient’s hospital stay. The CareView System suite can be easily configured to meet the individual privacy and security requirements of any hospital or nursing facility. The Health Insurance Portability and Accountability Act of 1996 (“HIPAA”) compliant, patient approved video record can be included as part of the patient’s medical record and serves as additional documentation of bedside care, procedures performed, patient and hospital ancillary activities, safety or care incidents, support to necessitate additional clinical services, and, if necessary, as evidence. Additional HIPAA-compliance features allow privacy options to be enabled at any time by the patient, nurse or physician.

In addition to patient safety and security, we also provide a suite of services to increase patient satisfaction scores and enhance the overall image of the hospital including first-run on-demand movies, Internet access via the patient’s television, and video visits with family and friends from most places throughout the world. Through continued investment in patient care technology, our products and services help hospitals and assisted living facilities build a safe, high quality healthcare delivery system that best serves the patient, while striving for the highest level of satisfaction and comfort.

Events Occurring During Second Quarter 2015

On June 26, 2015, we entered into a Credit Agreement with PDL BioPharma, Inc., as administrative agent and lender (“the Lender”) (the “PDL Credit Agreement”). Under the PDL Credit Agreement, the Lender made available to us up to $40 million in two tranches of $20 million each. In the event that a milestone relating to the placement of 9,000 billable units occurs on or before October 31, 2015, the Lender will fund us $20 million (“Tranche One”). In the event that additional milestones relating to the placement of (i) the placement of 27,750 billable units and (ii) the Company recording earnings before interest, tax, depreciation, and amortization (EBITDA) of not less than $7,000,000 on an annualized basis for the three calendar month period prior to the funding (on or before June 30, 2017), the Lender will fund us an additional $20 million (“Tranche Two” and, together with Tranche One, the “Loans”). Outstanding borrowings under Tranche One bear interest at the rate of 13.5% per annum, payable quarterly in arrears. Outstanding borrowings under Tranche Two bear interest at the rate of 13.0% per annum, payable quarterly in arrears.

Principal repayment under each of Tranche One and Tranche Two will commence on the ninth interest payment date. We may elect to pay a portion of the interest due in the form of additional Loans during the first eight interest payment dates. Each tranche will mature on the fifth anniversary of the date borrowed. We may elect to prepay the Loans at any time without any premium or penalty, subject to certain conditions.

The obligations under the PDL Credit Agreement are secured by a pledge of substantially all of the assets of the Company and certain of its domestic subsidiaries.

The PDL Credit Agreement contains customary affirmative covenants for transactions of this type and other affirmative covenants agreed to by the parties, including, among others, the provision of annual and quarterly reports, maintenance of property, insurance, compliance with laws and contractual obligations and payment of taxes. The PDL Credit Agreement contains customary negative covenants for transactions of this type and other negative covenants agreed to by the parties, including, among others, restrictions on the incurrence of indebtedness, the granting of liens, making restricted payments and investments, entering into affiliate transactions and transferring assets.

The PDL Credit Agreement also provides for a number of customary events of default, including payment, bankruptcy, covenant, representation and warranty and judgment defaults.

We had no relationship with the Lender, material or otherwise, prior to entering into the PDL Credit Agreement.

23

Contemporaneously with the execution of the PDL Credit Agreement, we issued the Lender a warrant to purchase 4,444,445 shares of our Common Stock at an exercise price of $0.45 per share, subject to adjustment as described therein (the “PDL Warrant”). The PDL Warrant expires on June 26, 2025.

In addition, contemporaneously with the execution of the PDL Credit Agreement on June 26, 2015:

· The Company and the Lender executed a Registration Rights Agreement pursuant to which we agreed to provide the Lender with certain registration rights with respect to the shares of common stock issuable upon exercise of the Warrant (the “PDL RRA”);

· the Company, the Lender, CareView Communications, Inc., a Texas corporation and a subsidiary of the Company (“CareView TX”) and CareView Operations, LLC, a Texas limited liability company and a subsidiary of the Company (“CareView LLC”) executed a Guarantee and Collateral Agreement (the “Guarantee and Collateral Agreement”) pursuant to which certain of our subsidiaries guaranteed the Company’s performance of its obligations under the PDL Credit Agreement and granted the Lender a security interest in such subsidiaries’ tangible and intangible assets securing the Company’s performance of the same;

· CareView TX executed (i) a Patent Security Agreement (the “Patent Security Agreement”) and (ii) a Trademark Security Agreement (the “Trademark Security Agreement”) pursuant to which CareView TX granted the Lender a security interest in CareView TX’s tangible and intangible assets securing the Company’s performance of its obligations under the PDL Credit Agreement;

· the Company, the Lender, HealthCor Partners Fund, LP (“HealthCor Partners”), HealthCor Hybrid Offshore Master Fund, LP (“HealthCor Hybrid” and, together with HealthCor Partners, the “HealthCor Funds”) and the Second Lien Claimholders (as defined therein) executed a Subordination and Intercreditor Agreement (the “Subordination and Intercreditor Agreement”) pursuant to which we granted first-priority liens on our and CareView TX’s pledged assets to the Lender and second-priority liens on such pledged assets to the HealthCor Funds and the Second Lien Claimholders (as defined therein);

· the Company, the HealthCor Funds and the other investors named therein executed a Seventh Amendment to Note and Warrant Purchase Agreement dated April 21, 2011, as amended (the “Note and Warrant Purchase Agreement”), pursuant to which the Note and Warrant Purchase Agreement was amended to permit the Company to enter into and the perform its obligations under the PDL Credit Agreement (the “Seventh Amendment to NWPA”);

· the Company and the HealthCor Funds executed an Amendment to Registration Rights Agreement dated April 21, 2011 (the “HC RRA”) pursuant to which the HC RRA was amended to make its priority of registration consistent with the PDL RRA (the “Amendment to HC RRA”); and

24

· the Company entered into the following allonges with respect to its Senior Secured Convertible Notes issued pursuant to the Note and Warrant Purchase Agreement: Allonge No. 1 to the Senior Secured Convertible Note (issued April 21, 2011) by and between the Company and HealthCor Partners, Allonge No. 1 to Senior Secured Convertible Note (issued April 21, 2011) by and between the Company and HealthCor Hybrid, Allonge No. 1 to Senior Secured Convertible Note (issued January 31, 2012) by and between the Company and HealthCor Partners, Allonge No. 1 to Senior Secured Convertible Note (issued January 31, 2012) by and between the Company and HealthCor Hybrid, Allonge No. 1 to Senior Secured Convertible Note (issued January 16, 2014) by and between the Company and HealthCor Partners, Allonge No. 1 to Senior Secured Convertible Note (issued January 16, 2014) by and between the Company and HealthCor Hybrid, and Allonge No. 1 to Senior Secured Convertible Notes (issued February 17, 2015) by and among the Company, HealthCor Partners and certain investors named therein (collectively, the “Allonges”). The Allonges amended (i) the Senior Secured Convertible Notes (issued April 21, 2011) to extend, in the event that Tranche Two is funded, the maturity date for such notes to 90 days after the earlier of the Tranche Two maturity date or repayment date, but not later than December 31, 2022 and (ii) the Senior Secured Convertible Notes (issued January 31, 2012) to set the maturity date at January 30, 2022 and, in the event that Tranche Two is funded, to extend such maturity date to 90 days after the earlier of the Tranche Two maturity date or repayment date, but not later than December 31, 2022. The Allonges also made certain other amendments to each of the Senior Secured Convertible Notes issued under the Note and Warrant Purchase Agreement, including to subordinate the notes to the Loans and to increase certain event of default acceleration and payment thresholds.

The foregoing descriptions of the PDL Credit Agreement, the Warrant, the PDL RRA, the Guarantee and Collateral Agreement, the Patent Security Agreement, the Trademark Security Agreement, the Subordination and Intercreditor Agreement, the Seventh Amendment to NWPA and the Amendment to HC RRA are qualified, in their entirety, by reference to each agreement, copies of which are attached as exhibits to our Current Report on Form 8-K filed on June 30, 2015 and incorporated by reference herein. The foregoing description of the Allonges are qualified, in their entirety, by reference to each agreement, copies of which are attached as exhibits to this Quarterly Report on Form 10-Q and incorporated by reference herein.

Summary of Product and Service Usage

The following table shows the number of healthcare facilities using our products and services including the number of installed hospitals, installed units and billable units as of July 31, 2015. The table also shows the total number of staffed beds under contract, potential available beds at hospitals under contract and total number of units in negotiation currently in negotiations.

There are no assurances that the pilot programs will be extended or the pending proposals will be approved to ultimately result in the number of estimated beds. Further, there are no assurances that we will have access to the total number of staffed beds in each healthcare facility.

Installed Hospitals	Installed Units	Billable Units	Total Staffed Beds in Contracted/ Pilot Hospitals	Potential Units Available Under Current Contract/ Pilot Contracts (*)	Units in Negotiation Prior to Contract/ Pilot
102	8,535	7,273	118,291	46,279	17,576

______________

(*) This number represents management’s best estimate of the number of units available to us in hospitals that are currently under contract or pilot agreement. We assume that in any given acute care facility, our products and services are appropriate for deployment in approximately 70% of the total staffed beds. If we have specific information from a current contracted or pilot hospital that the number of potential units in that hospital is either higher or lower than 70%, specific number has been used in the aggregate estimate.

25

Results of Operations

Three months ended June 30, 2015 compared to three months ended June 30, 2014

	Three months ended June 30,
	2015			2014			Change
	(000’s)
Revenue	$	1,266		$	698		$	568
Operating expenses		3,210			2,411			799
Operating loss		(1,944	)		(1,713	)		(231	)
Other, net		(1,991	)		(1,997	)		6
Net loss		(3,935	)		(3,710	)		(225	)
Net income (loss) attributable to noncontrolling interest		(17	)		(17	)		—
Net loss attributed to CareView	$	(3,918	)	$	(3,693	)	$	(225	)

Revenue

Revenue increased approximately $568,000 for the three months ended June 30, 2015 as compared to the same period in 2014. This increase is a direct result in the number of hospitals with billable units improving from 81 on June 30, 2014 to 85 on June 30, 2015. Billable units (RCPs and Nurse Stations) increased by 1,486 units during the three months ended June 30, 2015 (5,411 at March 31, 2015 to 6,897 at June 30, 2015 as compared to 881 units during the three months ended June 30, 2014 (3,446 at March 31, 2014 to 4,327 at June 30, 2014.

Operating Expenses

Our principal operating costs include the following items as a percentage of total operating expense.

	Three Months Ended June 30,
	2015			2014
Human resource costs, including non-cash compensation		44	%		40	%
Depreciation and amortization		14	%		17	%
Product deployment costs		14	%		10	%
Travel and entertainment expense		12	%		13	%
Other expenses, net		11	%		12	%
Professional and consulting costs		5	%		8	%

Operating expenses increased by 33% as a result of the following items:

		(000’s)
Increase in human resource costs, including non-cash compensation	$	417
Increase in product deployment costs		190
Increase in all other expenses, net		103
Increase in travel and entertainment expense		94
Increase in depreciation and amortization		35
Decrease in professional and consulting costs		(40	)
	$	799

26

We had 70 employees at June 30, 2015 compared to 43 at June 30, 2014. This increase of approximately $445,000 is a direct result of the increase in personnel.

The increase in product deployment costs of approximately $190,000 is directly related to the above mentioned increases in billable and installed units.

Other operating expense increased by approximately $103,000 for the three months ended June 30, 2015 in comparison to the same period in 2014, primarily a result of our increased participation at industry trade shows and conferences.

The increase of approximately 64,000 in travel and entertainment expense is directly related to the addition of new hospital contracts and the resulting product deployment during the three months ended June 30, 2015.

Professional and consulting fees decreased approximately $40,000 primarily as a result of the termination of certain consulting agreements and reduction in audit and accounting fees, offset by an increase in legal and other professional fees.

Other, net

Other non-operating income and expense decreased by approximately $6,000 for the three months ended June 30, 2015 in comparison to the same period in 2014, primarily a result of a favorable change in fair value of warrant liability related to warrants sold in conjunction with our April 2013 private placement totaling approximately $169,000, partially offset by an increase in interest expense related to our funding transactions.

Net Loss Attributable to CareView Communications, Inc.

As a result of the factors above, and after applying the $17,000 net loss attributed to noncontrolling interests, our second quarter of 2015 net loss of approximately $3,918,000 increased $225,000, or 6%, as compared to the $3,693,000 net loss for the second quarter of 2014.

Six months ended June 30, 2015 compared to six months ended June 30, 2014

	Six months ended June 30,
	2015			2014			Change
	(000’s)
Revenue	$	2,267		$	1,318		$	949
Operating expenses		5,717			4,591			1,126
Operating loss		(3,450	)		(3,273	)		(177	)
Other, net		(4,273	)		(4,605	)		332
Net loss		(7,723	)		(7,878	)		(155	)
Net income (loss) attributable to noncontrolling interest		(33	)		(33	)		—
Net loss attributed to CareView	$	(7,690	)	$	(7,845	)	$	(155	)

Revenue

Revenue increased approximately $949,000 for the six months ended June 30, 2015 as compared to the same period in 2014. As stated above, this increase is a direct result of hospitals with billable units improving from 81 on June 30, 2014 to 85 on June 30, 2015. Billable units (RCPs and Nurse Stations) increased by 2,021 units during the six months ended June 30, 2015 (4,876 at December 31, 2014 to 6,897 at June 31, 2015 as compared to 1,035 units during the six months ended June 30, 2014 (3,292 at December 31, 2013 to 4,327 at June 30, 2014.

27

Operating Expenses

Our principal operating costs include the following items as a percentage of total operating expense.

	Six Months Ended June 30,
	2015			2014
Human resource costs, including non-cash compensation		46	%		42	%
Depreciation and amortization		15	%		18	%
Travel and entertainment expense		12	%		11	%
Other expenses, net		12	%		11	%
Product deployment costs		11	%		10	%
Professional and consulting costs		4	%		8	%

Operating expenses increased by 25% as a result of the following items:

		(000’s)
Increase in human resource costs, including non-cash compensation	$	690
Increase in travel and entertainment expense		211
Increase in all other expenses, net		174
Increase in product deployment costs		161
Increase in depreciation and amortization		51
Decrease in professional and consulting costs		(161	)
	$	1,126

As discussed in the three month ending June 30, 2015 presentation above, the changes in human resource costs, travel and entertainment expense, and production deployment costs are directly related to our increase in personnel and our increase in hospitals (billable units). Professional and consulting fees decreased approximately $161,000 primarily as a result of the termination of certain consulting agreements (approximately $99,000) and reduction in legal fees (approximately $53,000).

Other, net

Other non-operating income and expense decreased by $332,000 for the six months ended June 30, 2015 in comparison to the same period in 2014, primarily a result of the favorable change in fair value of warrant liability related to warrants sold in conjunction with our April 2013 private placement totaling approximately $564,000, partially offset by an increase in interest expense related to our funding transactions.

Net Loss Attributable to CareView Communications, Inc.

As a result of the factors above, and after applying the $33,000 net loss attributed to noncontrolling interests, our net loss for the six months ended June 30, 2015 of $7,690,000 decreased $155,000, or 2%, as compared to the $7,845,000 net loss for the same period in 2014.

Liquidity and Capital Resources

Our cash position at June 30, 2015 was approximately $5,246,000.

Pursuant to the terms of a Note and Warrant Purchase Agreement dated April 21, 2011 (as subsequently amended) with HealthCor Partners Fund, LP and HealthCor Hybrid Offshore Master Fund, LP (“HealthCor”) we are required to maintain a minimum cash balance $2,000,000 (see NOTE 11 in the accompanying condensed consolidated financial statements for further details), and we are in compliance with the minimum cash balance as of the date of this filing.

28

Our continued successful operation is dependent upon us achieving positive cash flow through operations while maintaining adequate liquidity. We expect that the cash on hand, as well as our existing and projected cash flow from billable contracts, will enable us to continue to operate for the next twelve month period. We believe that our sales and marketing plan to attract new business and our ongoing deployment and installation of units under existing hospital agreements, will meet our near-term cash needs and will help us achieve future operating profitability.

At present, we have sufficient inventory to install and service a select number of large customers, but eventually we will need to address additional capital requirements. To that end, on June 26, 2015, we entered into the PDL Credit Agreement pursuant to which the Lender will make available to us up to $40 million in two tranches of $20 million each with each tranche contingent upon us meeting certain milestones (see NOTE 12 in the accompanying condensed consolidated financial statements for further details). No funds were available on the PDL Credit Agreement at June 30, 2015.

Off-Balance Sheet Arrangements

As of June 30, 2015, we had no material off-balance sheet arrangements.

In the ordinary course of business, we enter into agreements with third parties that include indemnification provisions which, in our judgment, are normal and customary for companies in our industry sector. These agreements are typically with business partners, clinical sites, and suppliers. Pursuant to these agreements, we generally agree to indemnify, hold harmless, and reimburse indemnified parties for losses suffered or incurred by the indemnified parties with respect to our product candidates, use of such product candidates, or other actions taken or omitted by us. The maximum potential amount of future payments we could be required to make under these indemnification provisions is unlimited. We have not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. As a result, the estimated fair value of liabilities relating to these provisions is minimal. Accordingly, we have no liabilities recorded for these provisions as of June 30, 2015.

In the normal course of business, we may be confronted with issues or events that may result in a contingent liability. These generally relate to lawsuits, claims, environmental actions or the actions of various regulatory agencies. We consult with counsel and other appropriate experts to assess the claim. If, in our opinion, we have incurred a probable loss as set forth by accounting principles generally accepted in the U.S., an estimate is made of the loss and the appropriate accounting entries are reflected in our financial statements. After consultation with legal counsel, we do not anticipate that liabilities arising out of currently threatened lawsuits and claims, if any, will have a material adverse effect on our financial position, results of operations or cash flows.

Critical Accounting Estimates

Please refer to our Annual Report on Form 10-K for the year ended December 31, 2014 filed with the Commission on March 31, 2015 and incorporated herein by reference, for detailed explanations of our critical accounting estimates, which have not changed significantly during the six months ended June 30, 2015.

New Accounting Pronouncements

There have been no material changes to our significant accounting policies as summarized in NOTE 2 of our Annual Report on Form 10-K for the year ended December 31, 2014. We do not expect that the adoption of any recent accounting pronouncements will have a material impact on our accompanying condensed consolidated financial statements.

Recent Events

None.

29

Item 3.    Quantitative and Qualitative Disclosures about Market Risk

None.

Item 4.    Controls and Procedures

Disclosure Controls and Procedures

Disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports filed or submitted under the Securities Exchange Act of 1934 (the “Exchange Act”) is recorded, processed, summarized and reported, within the time period specified in the SEC’s rules and forms and is accumulated and communicated to our management, as appropriate, in order to allow timely decisions in connection with required disclosure.

Evaluation of Disclosure Controls and Procedures

Pursuant to Rule 13a-15(b) under the Securities Exchange Act of 1934 (“Exchange Act”), we carried out an evaluation with the participation of our management, including Steve G. Johnson, our Chief Executive Officer (“CEO”) and principal executive officer, and L. Allen Wheeler, our principal financial officer and chief accounting officer, of the effectiveness of our disclosure controls and procedures (as defined under Rule 13a-15(e) under the Exchange Act) as of the end of the period covered by this Report.

Based upon that evaluation, our CEO and Chief Accounting Officer concluded that our disclosure controls and procedures were effective as of June 30, 2015 to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act, is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our CEO and Chief Accounting Officer, as appropriate, to allow timely decisions regarding required disclosure.

Changes in Internal Controls

During the three months ended June 30, 2015, there were no changes in our internal control over financial reporting that occurred that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION

Item 1.    Legal Proceedings.

None.

Item 1A. Risk Factors.

Our Company is a “smaller reporting company” as defined by Rule 12b-2 of the Exchange Act, and as such, is not required to provide the information required under this Item.

Item 2.    Unregistered Sales of Equity Securities and Use of Proceeds.

None.

Item 3.    Defaults Upon Senior Securities.

None.

30

Item 4.    Mine Safety Disclosures.

Not applicable.

Item 5.    Other Information.

None.

Item 6.    Exhibits.

Exhibit No.	Date of Document	Name of Document
10.01	06/26/15	Credit Agreement between the Company, CareView TX and the Lender(1)
10.02	06/26/15	Subordination and Intercreditor Agreement between the Company, the Lender, the HealthCor Funds and the Second Lien Claimholders(1)
10.03	06/26/15	Patent Security Agreement of CareView TX(1)
10.04	06/26/15	Trademark Security Agreement of CareView TX(1)
10.05	06/26/15	Guarantee and Collateral Agreement between the Company, CareView TX, CareView LLC and the Lender(1)
10.06	06/26/15	Registration Rights Agreement between the Company and the Lender(1)
10.07	06/26/15	Warrant to purchase 4,444,445 shares of the Company’s common stock issued to the Lender(1)
10.08	06/26/15	Seventh Amendment to Note and Warrant Purchase Agreement between the Company, the HealthCor Funds and the Investors named therein(1)
10.09	06/26/15	Amendment to Registration Rights Agreement between the Company and the HealthCor Funds(1)
10.10	06/26/15	Allonge No. 1 to the Senior Secured Convertible Note (issued April 21, 2011) by and between the Company and HealthCor Partners*
10.11	06/26/15	Allonge No. 1 to Senior Secured Convertible Note (issued April 21, 2011) by and between the Company and HealthCor Hybrid*
10.12	06/26/15	Allonge No. 1 to Senior Secured Convertible Note (issued January 31, 2012) by and between the Company and HealthCor Partners*
10.13	06/26/15	Allonge No. 1 to Senior Secured Convertible Note (issued January 31, 2012) by and between the Company and HealthCor Hybrid*
10.14	06/26/15	Allonge No. 1 to Senior Secured Convertible Note (issued January 16, 2014) by and between the Company and HealthCor Partners*
10.15	06/26/15	Allonge No. 1 to Senior Secured Convertible Note (issued January 16, 2014) by and between the Company and HealthCor Hybrid*
10.16	06/26/15	Allonge No. 1 to Senior Secured Convertible Notes (issued February 27, 2015) by and among the Company, HealthCor Partners and certain investors named therein*
31.1	8/14/15	Certification of Chief Executive Officer of Periodic Report pursuant to Rule 13a-14a and Rule 14d-14(a).*
31.2	8/14/15	Certification of Chief Financial Officer of Periodic Report pursuant to Rule 13a-14a and Rule 15d-14(a).*
32.1	8/14/15	Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350.*
32.2	8/14/15	Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350.*
101.INS	n/a	XBRL Instance Document*
101.SCH	n/a	XBRL Taxonomy Extension Schema Document*
101.CAL	n/a	XBRL Taxonomy Extension Calculation Linkbase Document*
101.DEF	n/a	XBRL Taxonomy Extension Definition Linkbase Document*
101.LAB	n/a	XBRL Taxonomy Extension Label Linkbase Document*
101.PRE	n/a	XBRL Taxonomy Extension Presentation Linkbase Document*

___________________

* Filed herewith.

⁽¹⁾ Incorporated by reference to the corresponding exhibit filed with our Current Report on Form 8-K on June 30, 2014.

31

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

DATE: August 14, 2015

CAREVIEW COMMUNICATIONS, INC.
By:	/s/ Steven G. Johnson
	Steven G. Johnson
	Chief Executive Officer
	Principal Executive Officer
By:	/s/ L. Allen Wheeler
	L. Allen Wheeler
	Principal Financial Officer
	Chief Accounting Officer

32

EX-10.10

CareView Communications, Inc, 10-Q

Exhibit 10.10

HEALTHCOR PARTNERS FUND, L.P.

ALLONGE NO. 1 TO SENIOR SECURED CONVERTIBLE NOTE

(issued April 21, 2011)

June 26, 2015

This Allonge No. 1 to Senior Secured Convertible Note (this “Allonge”) shall be affixed to that certain Senior Secured Convertible Note dated April 21, 2011 (the “Note”), issued in the original principal amount of $9,316,000, made by CareView Communications, Inc., a Nevada corporation (the “Company”) and payable to the order of HealthCor Partners Fund, L.P. (the “Holder”), and shall become a permanent part thereof and shall amend the Note as provided therein.

1.Amendment to Legend. The Note is hereby amended to delete the third paragraph of the legend on the cover page thereof and to replace it with the following:

NOTWITHSTANDING ANYTHING HEREIN TO THE CONTRARY, THE RIGHTS AND REMEDIES GRANTED TO THE HOLDER PURSUANT TO THIS NOTE, THE LIEN AND SECURITY INTEREST GRANTED TO THE AGENT SECURING THIS NOTE AND THE EXERCISE OF ANY RIGHT OR REMEDY BY THE HOLDER OR AGENT RELATING TO THIS NOTE ARE SUBJECT TO THE PROVISIONS OF THE SUBORDINATION AND INTERCREDITOR AGREEMENT DATED AS OF JUNE 26, 2015 (AS AMENDED, AMENDED AND RESTATED, SUPPLEMENTED OR OTHERWISE MODIFIED FROM TIME TO TIME IN ACCORDANCE WITH THE TERMS THEREOF, THE “INTERCREDITOR AGREEMENT”), AMONG PDL BIOPHARMA, INC. AND EACH OF THE NOTE INVESTORS PARTY TO THAT CERTAIN NOTE AND WARRANT PURCHASE AGREEMENT DATED AS OF APRIL 21, 2011, AS SUBSEQUENTLY AMENDED, AND CERTAIN OTHER PERSONS PARTY OR THAT MAY BECOME PARTY THERETO FROM TIME TO TIME. IN THE EVENT OF ANY CONFLICT BETWEEN THE TERMS OF THE INTERCREDITOR AGREEMENT AND THIS NOTE, THE PURCHASE AGREEMENT AND THE OTHER TRANSACTION DOCUMENTS (AS DEFINED IN THE PURCHASE AGREEMENT), THE TERMS OF THE INTERCREDITOR AGREEMENT SHALL GOVERN AND CONTROL.

2.Amendment to Maturity Date. The second sentence of Section 1 of the Note is hereby deleted and replaced with the following:

The “Maturity Date” shall be April 20, 2021; provided, that if the Tranche Two Funding Date shall occur under the PDL Credit Agreement, then the “Maturity Date” shall be 90 days after the earlier of (i) the Tranche Two Maturity Date and (ii) the date on which the Tranche Two Loan has been repaid in full, but in no event earlier than April 20, 2021; provided further, that the Maturity Date shall not be extended beyond December 31, 2022.

3.Amendment to Event of Default Acceleration Threshold. Section 4(a)(iii) of the Note is amended and restated in its entirety as follows:

“(iii) any acceleration prior to maturity of any Indebtedness referred to in clause (a) or (b) of the definition thereof of the Company or any of its Subsidiaries consisting of principal individually or in the aggregate equal to or greater than $500,000;”

4.Amendment to Event of Default Payment Threshold. Section 4(a)(xii) of the Note is amended and restated in its entirety as follows:

“(xii) the Company or any Subsidiary shall fail to make any payment (whether of principal, interest or otherwise and regardless of amount) in respect of any Indebtedness in excess of $500,000 (“Material Indebtedness”), when and as the same shall become due and payable, after giving effect to any grace period with respect thereto;”

5.Defined Terms. Section 23 of the Note shall be amended to add the following at the end thereof:

(u) “PDL Credit Agreement” means that certain Credit Agreement dated as of June 26, 2015, by and among the Company, CareView Communications, Inc., a Texas corporation, as Borrower, PDL Biopharma, Inc., as Lender, and PDL Biopharma, Inc., as Agent.

(v) “Tranche Two Funding Date,” “Tranche Two Loan” and “Tranche Two Maturity Date” shall each have the meanings given to such term under the PDL Credit Agreement.

6.No Further Amendments; Authorization to Affix to Note. Except as specifically amended hereby, the Note shall remain in full force and effect. The Company hereby authorizes the Holder to affix this Allonge to the Note and it shall for all purposes henceforth be part of the Note.

 [Signature Pages Follow]

IN WITNESS WHEREOF, the Company has caused this Allonge to be executed by its officer thereunto duly authorized, as of the date first above written.

COMPANY
CAREVIEW COMMUNICATIONS, INC.,
a Nevada corporation
By:	/s/ Steven Johnson
Name:	Steven Johnson
Title:	Chief Executive Officer

AGREED AND ACCEPTED:

HOLDER:

HEALTHCOR PARTNERS FUND, L.P.

By:	HealthCor Partners Management L.P., as Manager
By:	HealthCor Partners Management, G.P., LLC, as General Partner
By:	/s/ Jeffrey Lightcap
Name:	Jeffrey Lightcap
Title:	Senior Managing Director

EX-10.11

CareView Communications, Inc, 10-Q

Exhibit 10.11

HEALTHCOR HYBRID OFFSHORE MASTER FUND, L.P.

ALLONGE NO. 1 TO SENIOR SECURED CONVERTIBLE NOTE

(issued April 21, 2011)

June 26, 2015

This Allonge No. 1 to Senior Secured Convertible Note (this “Allonge”) shall be affixed to that certain Senior Secured Convertible Note dated April 21, 2011 (the “Note”), issued in the original principal amount of $10,684,000, made by CareView Communications, Inc., a Nevada corporation (the “Company”) and payable to the order of HealthCor Hybrid Offshore Master Fund, L.P. (the “Holder”), and shall become a permanent part thereof and shall amend the Note as provided therein.

1.Amendment to Legend. The Note is hereby amended to delete the third paragraph of the legend on the cover page thereof and to replace it with the following:

NOTWITHSTANDING ANYTHING HEREIN TO THE CONTRARY, THE RIGHTS AND REMEDIES GRANTED TO THE HOLDER PURSUANT TO THIS NOTE, THE LIEN AND SECURITY INTEREST GRANTED TO THE AGENT SECURING THIS NOTE AND THE EXERCISE OF ANY RIGHT OR REMEDY BY THE HOLDER OR AGENT RELATING TO THIS NOTE ARE SUBJECT TO THE PROVISIONS OF THE SUBORDINATION AND INTERCREDITOR AGREEMENT DATED AS OF JUNE 26, 2015 (AS AMENDED, AMENDED AND RESTATED, SUPPLEMENTED OR OTHERWISE MODIFIED FROM TIME TO TIME IN ACCORDANCE WITH THE TERMS THEREOF, THE “INTERCREDITOR AGREEMENT”), AMONG PDL BIOPHARMA, INC. AND EACH OF THE NOTE INVESTORS PARTY TO THAT CERTAIN NOTE AND WARRANT PURCHASE AGREEMENT DATED AS OF APRIL 21, 2011, AS SUBSEQUENTLY AMENDED, AND CERTAIN OTHER PERSONS PARTY OR THAT MAY BECOME PARTY THERETO FROM TIME TO TIME. IN THE EVENT OF ANY CONFLICT BETWEEN THE TERMS OF THE INTERCREDITOR AGREEMENT AND THIS NOTE, THE PURCHASE AGREEMENT AND THE OTHER TRANSACTION DOCUMENTS (AS DEFINED IN THE PURCHASE AGREEMENT), THE TERMS OF THE INTERCREDITOR AGREEMENT SHALL GOVERN AND CONTROL.

2.Amendment to Maturity Date. The second sentence of Section 1 of the Note is hereby deleted and replaced with the following:

The “Maturity Date” shall be April 20, 2021; provided, that if the Tranche Two Funding Date shall occur under the PDL Credit Agreement, then the “Maturity Date” shall be 90 days after the earlier of (i) the Tranche Two Maturity Date and (ii) the date on which the Tranche Two Loan has been repaid in full, but in no event earlier than April 20, 2021; provided further, that the Maturity Date shall not be extended beyond December 31, 2022.

3.Amendment to Event of Default Acceleration Threshold. Section 4(a)(iii) of the Note is amended and restated in its entirety as follows:

“(iii) any acceleration prior to maturity of any Indebtedness referred to in clause (a) or (b) of the definition thereof of the Company or any of its Subsidiaries consisting of principal individually or in the aggregate equal to or greater than $500,000;”

4.Amendment to Event of Default Payment Threshold. Section 4(a)(xii) of the Note is amended and restated in its entirety as follows:

“(xii) the Company or any Subsidiary shall fail to make any payment (whether of principal, interest or otherwise and regardless of amount) in respect of any Indebtedness in excess of $500,000 (“Material Indebtedness”), when and as the same shall become due and payable, after giving effect to any grace period with respect thereto;”

5.Defined Terms. Section 23 of the Note shall be amended to add the following at the end thereof:

(u) “PDL Credit Agreement” means that certain Credit Agreement dated as of June 26, 2015, by and among the Company, CareView Communications, Inc., a Texas corporation, as Borrower, PDL Biopharma, Inc., as Lender, and PDL Biopharma, Inc., as Agent.

(v) “Tranche Two Funding Date,” “Tranche Two Loan” and “Tranche Two Maturity Date” shall each have the meanings given to such term under the PDL Credit Agreement.

6.No Further Amendments; Authorization to Affix to Note. Except as specifically amended hereby, the Note shall remain in full force and effect. The Company hereby authorizes the Holder to affix this Allonge to the Note and it shall for all purposes henceforth be part of the Note.

[Signature Pages Follow]

  IN WITNESS WHEREOF, the Company has caused this Allonge to be executed by its officer thereunto duly authorized, as of the date first above written.

COMPANY
CAREVIEW COMMUNICATIONS, INC.,
a Nevada corporation
By:	/s/ Steven Johnson
Name:	Steven Johnson
Title:	Chief Executive Officer

AGREED AND ACCEPTED:

HOLDER:

HEALTHCOR HYBRID OFFSHORE MASTER FUND, L.P.

By:	HealthCor Hybrid Offshore G.P., LLC, as General Partner
By:	/s/ Joseph P. Healey
Name:	Joseph P. Healey
Title:	Co-CEO

EX-10.12

CareView Communications, Inc. 10-Q

EXHIBIT 10.12

HEALTHCOR PARTNERS FUND, L.P.

ALLONGE NO. 1 TO SENIOR SECURED CONVERTIBLE NOTE

(issued January 31, 2012)

June 26, 2015

This Allonge No. 1 to Senior Secured Convertible Note (this “Allonge”) shall be affixed to that certain Senior Secured Convertible Note dated January 31, 2012 (the “Note”), issued in the original principal amount of $2,329,000, made by CareView Communications, Inc., a Nevada corporation (the “Company”) and payable to the order of HealthCor Partners Fund, L.P. (the “Holder”), and shall become a permanent part thereof and shall amend the Note as provided therein.

1.             Amendment to Legend. The Note is hereby amended to delete the third paragraph of the legend on the cover page thereof and to replace it with the following:

NOTWITHSTANDING ANYTHING HEREIN TO THE CONTRARY, THE RIGHTS AND REMEDIES GRANTED TO THE HOLDER PURSUANT TO THIS NOTE, THE LIEN AND SECURITY INTEREST GRANTED TO THE AGENT SECURING THIS NOTE AND THE EXERCISE OF ANY RIGHT OR REMEDY BY THE HOLDER OR AGENT RELATING TO THIS NOTE ARE SUBJECT TO THE PROVISIONS OF THE SUBORDINATION AND INTERCREDITOR AGREEMENT DATED AS OF JUNE 26, 2015 (AS AMENDED, AMENDED AND RESTATED, SUPPLEMENTED OR OTHERWISE MODIFIED FROM TIME TO TIME IN ACCORDANCE WITH THE TERMS THEREOF, THE “INTERCREDITOR AGREEMENT”), AMONG PDL BIOPHARMA, INC. AND EACH OF THE NOTE INVESTORS PARTY TO THAT CERTAIN NOTE AND WARRANT PURCHASE AGREEMENT DATED AS OF APRIL 21, 2011, AS SUBSEQUENTLY AMENDED, AND CERTAIN OTHER PERSONS PARTY OR THAT MAY BECOME PARTY THERETO FROM TIME TO TIME. IN THE EVENT OF ANY CONFLICT BETWEEN THE TERMS OF THE INTERCREDITOR AGREEMENT AND THIS NOTE, THE PURCHASE AGREEMENT AND THE OTHER TRANSACTION DOCUMENTS (AS DEFINED IN THE PURCHASE AGREEMENT), THE TERMS OF THE INTERCREDITOR AGREEMENT SHALL GOVERN AND CONTROL.

2.             Amendment to Maturity Date. The second sentence of Section 1 of the Note is hereby deleted and replaced with the following:

The “Maturity Date” shall be January 30, 2022; provided, that if the Tranche Two Funding Date shall occur under the PDL Credit Agreement, then the “Maturity Date” shall be 90 days after the earlier of (i) the Tranche Two Maturity Date and (ii) the date on which the Tranche Two Loan has been repaid in full, but in no event earlier than January 30, 2022; provided further, that the Maturity Date shall not be extended beyond December 31, 2022.

3.             Amendment to Event of Default Acceleration Threshold. Section 4(a)(iii) of the Note is amended and restated in its entirety as follows:

“(iii) any acceleration prior to maturity of any Indebtedness referred to in clause (a) or (b) of the definition thereof of the Company or any of its Subsidiaries consisting of principal individually or in the aggregate equal to or greater than $500,000;”

4.             Amendment to Event of Default Payment Threshold. Section 4(a)(xii) of the Note is amended and restated in its entirety as follows:

“(xii) the Company or any Subsidiary shall fail to make any payment (whether of principal, interest or otherwise and regardless of amount) in respect of any Indebtedness in excess of $500,000 (“Material Indebtedness”), when and as the same shall become due and payable, after giving effect to any grace period with respect thereto;”

5.             Defined Terms. Section 23 of the Note shall be amended to add the following at the end thereof:

(u) “PDL Credit Agreement” means that certain Credit Agreement dated as of June26,, 2015, by and among the Company, CareView Communications, Inc., a Texas corporation, as Borrower, PDL Biopharma, Inc., as Lender, and PDL Biopharma, Inc., as Agent.

(v) “Tranche Two Funding Date,” “Tranche Two Loan” and “Tranche Two Maturity Date” shall each have the meanings given to such term under the PDL Credit Agreement.

5.             No Further Amendments; Authorization to Affix to Note. Except as specifically amended hereby, the Note shall remain in full force and effect. The Company hereby authorizes the Holder to affix this Allonge to the Note and it shall for all purposes henceforth be part of the Note.

IN WITNESS WHEREOF, the Company has caused this Allonge to be executed by its officer thereunto duly authorized, as of the date first above written.

COMPANY:
CAREVIEW COMMUNICATIONS, INC., a Nevada corporation
By:	/s/ Steven Johnson
Name:	Steven Johnson
Title:	Chief Executive Officer

AGREED AND ACCEPTED:

HOLDER:

HEALTHCOR PARTNERS FUND, L.P.

By:	HealthCor Partners Management L.P., as Manager
By:	HealthCor Partners Management, G.P., LLC, as General Partner
By:	/s/ Jeffrey Lightcap
Name:	Jeffrey Lightcap
Title:	Senior Managing Director

[Signature page to Allonge No. 1 to CareView Communications, Inc. Secured Convertible Note issued January 31, 2012 (HCP Fund)]

EX-10.13

CareView Communications, Inc. 10-Q

EXHIBIT 10.13

HEALTHCOR HYBRID OFFSHORE MASTER FUND, L.P.

ALLONGE NO. 1 TO SENIOR SECURED CONVERTIBLE NOTE

(issued January 31, 2012)

June 26, 2015

This Allonge No. 1 to Senior Secured Convertible Note (this “Allonge”) shall be affixed to that certain Senior Secured Convertible Note dated January 31, 2012 (the “Note”), issued in the original principal amount of $2,671,000, made by CareView Communications, Inc., a Nevada corporation (the “Company”) and payable to the order of HealthCor Hybrid Offshore Master Fund, L.P. (the “Holder”), and shall become a permanent part thereof and shall amend the Note as provided therein.

1.             Amendment to Legend. The Note is hereby amended to delete the third paragraph of the legend on the cover page thereof and to replace it with the following:

NOTWITHSTANDING ANYTHING HEREIN TO THE CONTRARY, THE RIGHTS AND REMEDIES GRANTED TO THE HOLDER PURSUANT TO THIS NOTE, THE LIEN AND SECURITY INTEREST GRANTED TO THE AGENT SECURING THIS NOTE AND THE EXERCISE OF ANY RIGHT OR REMEDY BY THE HOLDER OR AGENT RELATING TO THIS NOTE ARE SUBJECT TO THE PROVISIONS OF THE SUBORDINATION AND INTERCREDITOR AGREEMENT DATED AS OF JUNE 26, 2015 (AS AMENDED, AMENDED AND RESTATED, SUPPLEMENTED OR OTHERWISE MODIFIED FROM TIME TO TIME IN ACCORDANCE WITH THE TERMS THEREOF, THE “INTERCREDITOR AGREEMENT”), AMONG PDL BIOPHARMA, INC. AND EACH OF THE NOTE INVESTORS PARTY TO THAT CERTAIN NOTE AND WARRANT PURCHASE AGREEMENT DATED AS OF APRIL 21, 2011, AS SUBSEQUENTLY AMENDED, AND CERTAIN OTHER PERSONS PARTY OR THAT MAY BECOME PARTY THERETO FROM TIME TO TIME. IN THE EVENT OF ANY CONFLICT BETWEEN THE TERMS OF THE INTERCREDITOR AGREEMENT AND THIS NOTE, THE PURCHASE AGREEMENT AND THE OTHER TRANSACTION DOCUMENTS (AS DEFINED IN THE PURCHASE AGREEMENT), THE TERMS OF THE INTERCREDITOR AGREEMENT SHALL GOVERN AND CONTROL.

2.             Amendment to Maturity Date. The second sentence of Section 1 of the Note is hereby deleted and replaced with the following:

The “Maturity Date” shall be January 30, 2022; provided, that if the Tranche Two Funding Date shall occur under the PDL Credit Agreement, then the “Maturity Date” shall be 90 days after the earlier of (i) the Tranche Two Maturity Date and (ii) the date on which the Tranche Two Loan has been repaid in full, but in no event earlier than January 30, 2022; provided further, that the Maturity Date shall not be extended beyond December 31, 2022.

3.             Amendment to Event of Default Acceleration Threshold. Section 4(a)(iii) of the Note is amended and restated in its entirety as follows:

“(iii) any acceleration prior to maturity of any Indebtedness referred to in clause (a) or (b) of the definition thereof of the Company or any of its Subsidiaries consisting of principal individually or in the aggregate equal to or greater than $500,000;”

4.             Amendment to Event of Default Payment Threshold. Section 4(a)(xii) of the Note is amended and restated in its entirety as follows:

“(xii) the Company or any Subsidiary shall fail to make any payment (whether of principal, interest or otherwise and regardless of amount) in respect of any Indebtedness in excess of $500,000 (“Material Indebtedness”), when and as the same shall become due and payable, after giving effect to any grace period with respect thereto;”

5.             Defined Terms. Section 23 of the Note shall be amended to add the following at the end thereof:

(u) “PDL Credit Agreement” means that certain Credit Agreement dated as of June 26, 2015, by and among the Company, CareView Communications, Inc., a Texas corporation, as Borrower, PDL Biopharma, Inc., as Lender, and PDL Biopharma, Inc., as Agent.

(v) “Tranche Two Funding Date,” “Tranche Two Loan” and “Tranche Two Maturity Date” shall each have the meanings given to such term under the PDL Credit Agreement.

5.             No Further Amendments; Authorization to Affix to Note. Except as specifically amended hereby, the Note shall remain in full force and effect. The Company hereby authorizes the Holder to affix this Allonge to the Note and it shall for all purposes henceforth be part of the Note.

[Signature Pages Follow]

IN WITNESS WHEREOF, the Company has caused this Allonge to be executed by its officer thereunto duly authorized, as of the date first above written.

COMPANY:
CAREVIEW COMMUNICATIONS, INC., a Nevada corporation
By:	/s/ Steven Johnson
Name:	Steven Johnson
Title:	Chief Executive Officer

AGREED AND ACCEPTED:

HOLDER:

HEALTHCOR HYBRID OFFSHORE MASTER FUND, L.P.

By:	HealthCor Hybrid Offshore G.P., LLC, as General Partner
By:	/s/ Joseph P. Healey
Name:	Joseph P. Healey
Title:	Co-CEO

[Signature page to Allonge No. 1 to CareView Communications, Inc. Secured Convertible Note issued January 31, 2012 (Hybrid Fund)]

EX-10.14

CareView Communications, Inc. 10-Q

Exhibit 10.14

HEALTHCOR PARTNERS FUND, L.P.

ALLONGE NO. 1 TO SENIOR SECURED CONVERTIBLE NOTE

(issued January 16, 2014)

June 26, 2015

This Allonge No. 1 to Senior Secured Convertible Note (this “Allonge”) shall be affixed to that certain Senior Secured Convertible Note dated January 16, 2014 (the “Note”), issued in the original principal amount of $2,329,000, made by CareView Communications, Inc., a Nevada corporation (the “Company”) and payable to the order of HealthCor Partners Fund, L.P. (the “Holder”), and shall become a permanent part thereof and shall amend the Note as provided therein.

1.Amendment to Legend. The Note is hereby amended to delete the third paragraph of the legend on the cover page thereof and to replace it with the following:

NOTWITHSTANDING ANYTHING HEREIN TO THE CONTRARY, THE RIGHTS AND REMEDIES GRANTED TO THE HOLDER PURSUANT TO THIS NOTE, THE LIEN AND SECURITY INTEREST GRANTED TO THE AGENT SECURING THIS NOTE AND THE EXERCISE OF ANY RIGHT OR REMEDY BY THE HOLDER OR AGENT RELATING TO THIS NOTE ARE SUBJECT TO THE PROVISIONS OF THE SUBORDINATION AND INTERCREDITOR AGREEMENT DATED AS OF JUNE 26, 2015 (AS AMENDED, AMENDED AND RESTATED, SUPPLEMENTED OR OTHERWISE MODIFIED FROM TIME TO TIME IN ACCORDANCE WITH THE TERMS THEREOF, THE “INTERCREDITOR AGREEMENT”), AMONG PDL BIOPHARMA, INC. AND EACH OF THE NOTE INVESTORS PARTY TO THAT CERTAIN NOTE AND WARRANT PURCHASE AGREEMENT DATED AS OF APRIL 21, 2011, AS SUBSEQUENTLY AMENDED, AND CERTAIN OTHER PERSONS PARTY OR THAT MAY BECOME PARTY THERETO FROM TIME TO TIME. IN THE EVENT OF ANY CONFLICT BETWEEN THE TERMS OF THE INTERCREDITOR AGREEMENT AND THIS NOTE, THE PURCHASE AGREEMENT AND THE OTHER TRANSACTION DOCUMENTS (AS DEFINED IN THE PURCHASE AGREEMENT), THE TERMS OF THE INTERCREDITOR AGREEMENT SHALL GOVERN AND CONTROL.

2.Amendment to Event of Default Acceleration Threshold. Section 4(a)(iii) of the Note is amended and restated in its entirety as follows:

“(iii) any acceleration prior to maturity of any Indebtedness referred to in clause (a) or (b) of the definition thereof of the Company or any of its Subsidiaries consisting of principal individually or in the aggregate equal to or greater than $500,000;”

3.Amendment to Event of Default Payment Threshold. Section 4(a)(xii) of the Note is amended and restated in its entirety as follows:

“(xii) the Company or any Subsidiary shall fail to make any payment (whether of principal, interest or otherwise and regardless of amount) in respect of any Indebtedness in excess of $500,000 (“Material Indebtedness”), when and as the same shall become due and payable, after giving effect to any grace period with respect thereto;”

4.No Further Amendments; Authorization to Affix to Note. Except as specifically amended hereby, the Note shall remain in full force and effect. The Company hereby authorizes the Holder to affix this Allonge to the Note and it shall for all purposes henceforth be part of the Note.

[Signature Pages Follow]

IN WITNESS WHEREOF, the Company has caused this Allonge to be executed by its officer thereunto duly authorized, as of the date first above written.

COMPANY
CAREVIEW COMMUNICATIONS, INC.,
a Nevada corporation
By:	/s/ Steven Johnson
Name:	Steven Johnson
Title:	Chief Executive Officer

AGREED AND ACCEPTED:

HOLDER:

HEALTHCOR PARTNERS FUND, L.P.

By:	HealthCor Partners Management L.P., as Manager
By:	HealthCor Partners Management, G.P., LLC, as General Partner
By:	/s/ Jeffrey Lightcap
Name:	Jeffrey Lightcap
Title:	Senior Managing Director

EX-10.15

CareView Communications, Inc. 10-Q

Exhibit 10.15

HEALTHCOR HYBRID OFFSHORE MASTER FUND, L.P.

ALLONGE NO. 1 TO SENIOR SECURED CONVERTIBLE NOTE

(issued January 16, 2014)

June 26, 2015

This Allonge No. 1 to Senior Secured Convertible Note (this “Allonge”) shall be affixed to that certain Senior Secured Convertible Note dated January 16, 2014 (the “Note”), issued in the original principal amount of $2,671,000, made by CareView Communications, Inc., a Nevada corporation (the “Company”) and payable to the order of HealthCor Hybrid Offshore Master Fund, L.P. (the “Holder”), and shall become a permanent part thereof and shall amend the Note as provided therein.

1.Amendment to Legend. The Note is hereby amended to delete the third paragraph of the legend on the cover page thereof and to replace it with the following:

NOTWITHSTANDING ANYTHING HEREIN TO THE CONTRARY, THE RIGHTS AND REMEDIES GRANTED TO THE HOLDER PURSUANT TO THIS NOTE, THE LIEN AND SECURITY INTEREST GRANTED TO THE AGENT SECURING THIS NOTE AND THE EXERCISE OF ANY RIGHT OR REMEDY BY THE HOLDER OR AGENT RELATING TO THIS NOTE ARE SUBJECT TO THE PROVISIONS OF THE SUBORDINATION AND INTERCREDITOR AGREEMENT DATED AS OF JUNE 26, 2015 (AS AMENDED, AMENDED AND RESTATED, SUPPLEMENTED OR OTHERWISE MODIFIED FROM TIME TO TIME IN ACCORDANCE WITH THE TERMS THEREOF, THE “INTERCREDITOR AGREEMENT”), AMONG PDL BIOPHARMA, INC. AND EACH OF THE NOTE INVESTORS PARTY TO THAT CERTAIN NOTE AND WARRANT PURCHASE AGREEMENT DATED AS OF APRIL 21, 2011, AS SUBSEQUENTLY AMENDED, AND CERTAIN OTHER PERSONS PARTY OR THAT MAY BECOME PARTY THERETO FROM TIME TO TIME. IN THE EVENT OF ANY CONFLICT BETWEEN THE TERMS OF THE INTERCREDITOR AGREEMENT AND THIS NOTE, THE PURCHASE AGREEMENT AND THE OTHER TRANSACTION DOCUMENTS (AS DEFINED IN THE PURCHASE AGREEMENT), THE TERMS OF THE INTERCREDITOR AGREEMENT SHALL GOVERN AND CONTROL.

2.Amendment to Event of Default Acceleration Threshold. Section 4(a)(iii) of the Note is amended and restated in its entirety as follows:

“(iii) any acceleration prior to maturity of any Indebtedness referred to in clause (a) or (b) of the definition thereof of the Company or any of its Subsidiaries consisting of principal individually or in the aggregate equal to or greater than $500,000;”

3.Amendment to Event of Default Payment Threshold. Section 4(a)(xii) of the Note is amended and restated in its entirety as follows:

“(xii) the Company or any Subsidiary shall fail to make any payment (whether of principal, interest or otherwise and regardless of amount) in respect of any Indebtedness in excess of $500,000 (“Material Indebtedness”), when and as the same shall become due and payable, after giving effect to any grace period with respect thereto;”

4.No Further Amendments; Authorization to Affix to Note. Except as specifically amended hereby, the Note shall remain in full force and effect. The Company hereby authorizes the Holder to affix this Allonge to the Note and it shall for all purposes henceforth be part of the Note.

[Signature Page Follows]

IN WITNESS WHEREOF, the Company has caused this Allonge to be executed by its officer thereunto duly authorized, as of the date first above written.

COMPANY
CAREVIEW COMMUNICATIONS, INC.,
a Nevada corporation
By:	/s/ Steven Johnson
Name:	Steven Johnson
Title:	Chief Executive Officer

AGREED AND ACCEPTED:

HOLDER:

HEALTHCOR HYBRID OFFSHORE MASTER FUND, L.P.

By:	HealthCor Hybrid Offshore G.P., LLC, as General Partner
By:	/s/ Joseph P. Healey
Name:	Joseph P. Healey
Title:	Co-CEO

EX-10.16

CareView Communications, Inc. 10-Q

Exhibit 10.16

ALLONGE NO. 1 TO SENIOR SECURED CONVERTIBLE NOTES

(issued February 17, 2015)

June 26, 2015

This Allonge No. 1 to Senior Secured Convertible Notes (this “Allonge”) shall be affixed to each of those certain Senior Secured Convertible Notes dated February 17, 2015 (the “Notes” and each, a “Note”), issued in the original aggregate principal amount of $6,000,000, made by CareView Communications, Inc., a Nevada corporation (the “Company”), and payable to the order of the Holders specified therein (each, a “Holder”), and shall become a permanent part thereof and shall amend each such Note as provided by Section 11 of each such Note.

1.Amendment to Legend. The Note is hereby amended to insert the following paragraph at the end of the legend on the cover page thereof:

NOTWITHSTANDING ANYTHING HEREIN TO THE CONTRARY, THE RIGHTS AND REMEDIES GRANTED TO THE HOLDER PURSUANT TO THIS NOTE, THE LIEN AND SECURITY INTEREST GRANTED TO THE AGENT SECURING THIS NOTE AND THE EXERCISE OF ANY RIGHT OR REMEDY BY THE HOLDER OR AGENT RELATING TO THIS NOTE ARE SUBJECT TO THE PROVISIONS OF THE SUBORDINATION AND INTERCREDITOR AGREEMENT DATED AS OF JUNE 26, 2015 (AS AMENDED, AMENDED AND RESTATED, SUPPLEMENTED OR OTHERWISE MODIFIED FROM TIME TO TIME IN ACCORDANCE WITH THE TERMS THEREOF, THE “INTERCREDITOR AGREEMENT”), AMONG PDL BIOPHARMA, INC. AND EACH OF THE NOTE INVESTORS PARTY TO THAT CERTAIN NOTE AND WARRANT PURCHASE AGREEMENT DATED AS OF APRIL 21, 2011, AS SUBSEQUENTLY AMENDED, AND CERTAIN OTHER PERSONS PARTY OR THAT MAY BECOME PARTY THERETO FROM TIME TO TIME. IN THE EVENT OF ANY CONFLICT BETWEEN THE TERMS OF THE INTERCREDITOR AGREEMENT AND THIS NOTE, THE PURCHASE AGREEMENT AND THE OTHER TRANSACTION DOCUMENTS (AS DEFINED IN THE PURCHASE AGREEMENT), THE TERMS OF THE INTERCREDITOR AGREEMENT SHALL GOVERN AND CONTROL.

2.Amendment to Event of Default Acceleration Threshold. Section 4(a)(iii) of the Note is amended and restated in its entirety as follows:

“(iii) any acceleration prior to maturity of any Indebtedness referred to in clause (a) or (b) of the definition thereof of the Company or any of its Subsidiaries consisting of principal individually or in the aggregate equal to or greater than $500,000;”

3.Amendment to Event of Default Payment Threshold. Section 4(a)(xii) of the Note is amended and restated in its entirety as follows:

“(xii) the Company or any Subsidiary shall fail to make any payment (whether of principal, interest or otherwise and regardless of amount) in respect of any Indebtedness in excess of $500,000 (“Material Indebtedness”), when and as the same shall become due and payable, after giving effect to any grace period with respect thereto;”

4.No Further Amendments; Authorization to Affix to Note. Except as specifically amended hereby, the Note shall remain in full force and effect. The Company hereby authorizes each Holder to affix this Allonge to its Note and it shall for all purposes henceforth be part of the Note.

[Signature page follows]

IN WITNESS WHEREOF, the Company has caused this Allonge to be executed by its officer thereunto duly authorized, as of the date first above written.

COMPANY
CAREVIEW COMMUNICATIONS, INC.,
a Nevada corporation
By:	/s/ Steven Johnson
Name:	Steven Johnson
Title:	Chief Executive Officer

AGREED AND ACCEPTED:

By the MAJORITY FEBRUARY 2015 INVESTORS (as defined in the Notes)

on behalf of all Holders of the Notes: 

HEALTHCOR PARTNERS FUND, L.P.

By:	HealthCor Partners Management L.P., as Manager
By:	HealthCor Partners Management, G.P., LLC, as General Partner
By:	/s/ Jeffrey Lightcap
Name:	Jeffrey Lightcap
Title:	Senior Managing Director
/s/ Arthur B. Cohen
Arthur B. Cohen
/s/ Joseph B. Healey
Joseph B. Healey
/s/ Steven Johnson
Steven Johnson

EX-31.1

CareView Communications, Inc. 10-Q

Exhibit 31.1

CERTIFICATION PURSUANT TO 

SECTION 302 OF 

THE SARBANES-OXLEY ACT OF 2002

I, Steven G. Johnson, certify that:

(1) I have reviewed this quarterly report on Form 10-Q of CareView Communications, Inc.;

(2) Based on my knowledge, this report does not contain any untrue statements of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

(3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

(4) The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluations; and

d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

(5) The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of the internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

August 14, 2015	/s/ Steven G. Johnson
	Steven G. Johnson
	Chief Executive Officer
	Principal Executive Officer

EX-31.2

CareView Communications, Inc. 10-Q

Exhibit 31.2

CERTIFICATION PURSUANT TO

SECTION 302 OF 

THE SARBANES-OXLEY ACT OF 2002

I, L. Allen Wheeler, certify that:

(1) I have reviewed this quarterly report on Form 10-Q of CareView Communications, Inc.;

(2) Based on my knowledge, this report does not contain any untrue statements of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

(3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

(4) The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluations; and

d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

(5) The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of the internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

August 14, 2015	/s/ L. Allen Wheeler
	L. Allen Wheeler
	Principal Financial Officer
	Chief Account Officer

EX-32.1

CareView Communications, Inc. 10-Q

EXHIBIT 32.1

CERTIFICATION PURSUANT TO 

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of CareView Communications, Inc. (the “Company”) on Form 10-Q for the period ending June 30, 2015, as filed with the Securities and Exchange Commission (the “Report”), I, Steven G. Johnson, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1)	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

/s/ Steven G. Johnson

Steven G. Johnson

Chief Executive Officer

August 14, 2015

A signed original of this certification has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

EX-32.2

CareView Communications, Inc. 10-Q

EXHIBIT 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of CareView Communications, Inc. (the “Company”) on Form 10-Q for the period ending June 30, 2015, as filed with the Securities and Exchange Commission (the “Report”), I, L. Allen Wheeler, Principal Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1)	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

/s/ L. Allen Wheeler

L. Allen Wheeler

Principal Financial Officer

August 14, 2015

A signed original of this certification has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

XML

OTHER CURRENT LIABILITIES (Details) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
OTHER CURRENT LIABILITIES:
Accrued issuance costs	$ 550,000
Accrued taxes	201,270	$ 145,183
Accrued paid time off	89,359	87,319
Accrued travel and entertainment	79,097	35,000
Accrued insurance	75,832
Allowance for system removal	61,121	277,000
Accrued professional services	30,400	204,675
Other accrued liabilities	34,180	42,107
TOTAL OTHER CURRENT LIABILITIES	$ 1,121,259	$ 791,284

XML

OTHER CURRENT LIABILITIES (Tables)

6 Months Ended

Jun. 30, 2015

Other Current Liabilities Tables

Schedule of other current liabilities

Other current liabilities consist of the following:

	June 30, 2015		December 31, 2014
Accrued issuance costs	$	550,000	$	—
Accrued taxes		201,270		145,183
Accrued paid time off		89,359		87,319
Accrued travel and entertainment		79,097		35,000
Accrued insurance		75,832		—
Allowance for system removal		61,121		277,000
Accrued professional services		30,400		204,675
Other accrued liabilities		34,180		42,107
TOTAL OTHER CURRENT LIABILITIES	$	1,121,259	$	791,284

XML

VARIABLE INTEREST ENTITIES (Details 1) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Revenue	$ 1,266,391	$ 698,129	$ 2,266,945	$ 1,317,538
Network operations expense	1,304,973	811,178	2,135,067	1,412,400
General and administrative expense (cost recovery)	923,056	805,081	1,761,365	1,607,058
Depreciation	442,248	407,376	858,152	806,708
Total operating costs	3,209,876	2,410,892	5,717,001	4,590,542
Operating loss	(1,943,485)	(1,712,763)	(3,450,056)	(3,273,004)
Loss before taxes	$ (3,934,227)	(3,709,871)	(7,722,532)	(7,878,412)
Provision for taxes
Net loss attributable to noncontrolling interest	$ (16,482)	(17,087)	(32,704)	(32,927)
Net loss attributable to CareView Communications, Inc.	$ (3,917,745)	$ (3,692,784)	(7,689,828)	(7,845,485)
Variable Interest Entity [Member]
Revenue			14,194	14,259
Network operations expense			8,328	8,337
General and administrative expense (cost recovery)			1,485	1,473
Depreciation			24,464	25,264
Total operating costs			34,277	35,074
Operating loss			(20,083)	(20,815)
Other expense			(45,296)	(45,039)
Loss before taxes			(65,379)	(65,854)
Net loss			(65,379)	(65,854)
Net loss attributable to noncontrolling interest			(32,689)	(32,927)
Net loss attributable to CareView Communications, Inc.			$ (32,689)	$ (32,927)

XML

OTHER ASSETS (Details) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Finite-Lived Intangible Assets [Line Items]
Cost	$ 375,133	$ 322,606
Accumulated Amortization	81,175	61,323
Intangible assets, Net	293,958	261,283
Patents and trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Cost	323,669	271,142
Accumulated Amortization	42,354	26,157
Intangible assets, Net	281,315	244,985
Other intangible assets [Member]
Finite-Lived Intangible Assets [Line Items]
Cost	51,464	51,464
Accumulated Amortization	38,821	35,166
Intangible assets, Net	$ 12,643	$ 16,298

XML

STOCKHOLDERS' EQUITY

6 Months Ended

Jun. 30, 2015

Stockholders' Deficit:

STOCKHOLDERS' EQUITY

NOTE 3 – STOCKHOLDERS’ EQUITY

Warrants to Purchase Common Stock of the Company

We use the Black-Scholes-Merton option pricing model (“Black-Scholes Model”) to determine the fair value of warrants to purchase our Common Stock (the “Warrant(s)”) (except certain Warrants issued to HealthCor and Warrants issued pursuant to the terms our March 2013 private placement (the “Private Placement Warrants”). The Black-Scholes Model is an acceptable model in accordance with GAAP. The Black-Scholes Model requires the use of a number of assumptions including volatility of the stock price, risk-free interest rate, and the estimated term of the Warrant. Estimated volatility is a measure of the amount by which our stock price is expected to fluctuate each year during the expected life of the award. Our estimated volatility is an average of the historical volatility of our stock prices (and that of peer entities whose stock prices were publicly available). Our calculation of estimated volatility is based on historical stock prices over a period equal to the expected life of the awards. Where appropriate we used the historical volatility of peer entities due to the lack of sufficient historical data of our stock price during 2007-2009. The risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the term of the Warrant and is calculated by using the average daily historical stock prices through the day preceding the grant date.

The fair value of the above mentioned Warrants issued to HealthCor and the Private Placement Warrants was computed using the Binomial Lattice model, incorporating transaction details such as the price of our Common Stock, contractual terms, maturity and risk free rates, as well as assumptions about future financings, volatility, and holder behavior. Due to the down round provisions associated with the exercise price of these Warrants, we determined that the Binomial Lattice model was the most appropriate model for valuing these instruments.

Warrant Activity during the Six Months Ended June 30, 2015

On June 26, 2015, in conjunction with the PLD Credit Agreement, we issued a warrant to purchase 4,444,445 shares of our Common Stock, subject to adjustment as described therein (the “PDL Warrant”). The PDL Warrant has an exercise price of $0.45, a fair value of $1,257,778, and expires on June 26, 2025 (see NOTE 12 for further details).

On February 17, 2015, we entered into a Fifth Amendment to the Note and Warrant Purchase Agreement with HealthCor and certain other investors and agreed to sell and issue (i) additional notes in the initial aggregate principal amount of $6,000,000, with a conversion price per share equal to $0.52 (subject to adjustment for standard anti-dilution provisions) and (ii) additional Warrants for an aggregate of up to 3,692,307 shares of our Common Stock at an exercise price per share equal to $0.52 (subject to adjustment for standard anti-dilution provisions) (the “Fifth Amendment Warrants”). The fair value of the convertible debt and the Fifth Amendment Warrants was determined to be $7,336,615, resulting in a relative fair value of $1,093,105 for the Fifth Amendment Warrants on the date of grant (see NOTE 11 for further details)

On March 31, 2015, we issued HealthCor a Warrant for up to an aggregate of 1,000,000 shares of our Common Stock in consideration for certain prior waivers of the minimum cash balance requirement in the Purchase Agreement. This Warrant has an exercise price of $0.53 per share, expires on March 31, 2025 and has a fair value of $378,000 (see NOTE 11 for further details).

As of December 31, 2014, we recorded a warrant liability of $301,864 in our consolidated financial statements. At June 30, 2015, the Private Placement Warrants were re-valued with a fair value determination of $314,818, resulting in a difference of $12,954, which was included as change in fair value of warrant liability in other income and expense in the accompanying condensed consolidated financial statements.

Warrants to Purchase Common Stock of the Company (continued)

Warrant Activity during the Six Months Ended June 30, 2015 (continued)

During the six months ended June 30, 2015, warrants to purchase an aggregate of 2,892,686 shares of our Common Stock expired.

Warrant Activity during the Six Months Ended June 30, 2014

On January 16, 2014, we entered into a Fourth Amendment to the Note and Warrant Purchase Agreement with HealthCor and agreed to sell and issue (i) additional notes in the initial aggregate principal amount of $5,000,000, with a conversion price per share equal to $0.40 (subject to adjustment for standard anti-dilution provisions) and (ii) additional Warrants for an aggregate of up to 4,000,000 shares of our Common Stock at an exercise price per share equal to $0.40 (subject to adjustment for standard anti-dilution provisions) (the “Fourth Amendment Warrants”). The fair value of the convertible debt and the Fourth Amendment Warrants was determined to be $6,488,000, resulting in a relative fair value of $1,146,732 for the Fourth Amendment Warrants on the date of grant.

As of December 31, 2013, we recorded a warrant liability of $370,865 in our condensed consolidated financial statements. At June 30, 2014, the Private Placement Warrants were re-valued with a fair value determination of $948,206 and the difference of $577,341 was included as change in fair value of warrant liability in other income and expense in the accompanying condensed consolidated financial statements.

Options to Purchase Common Stock of the Company

On February 25, 2015, we established the CareView Communications, Inc. 2015 Stock Option Plan (the “2015 Plan”) pursuant to which 5,000,000 shares of Common Stock was reserved for issuance upon the exercise of options (“2015 Plan Option(s)”). The 2015 Plan was designed to serve as an incentive for retaining our qualified and competent key employees, officers and directors. The 2015 Plan Options vest over three years and have an exercise period of ten years from the date of issuance.

During the six months ended June 30, 2015, we granted options to purchase 1,815,000 shares of our Common Stock (the ‘‘Option(s)’’) to certain employees and members of our board of directors. We granted 1,300,000 Options to certain employees and members of our board of directors during the six months ended June 30, 2014. During those same six month periods, 77,837 and 15,000 Options, respectively, were canceled and 6,261,308 and 41,666 Options, respectively, expired.

A summary of our stock option activity and related information follows:

	Number of Shares Under Options			Weighted Average Exercise Price		Weighted   Average   Remaining   Contractual   Life		Aggregate Intrinsic Value
Balance at December 31, 2014		14,273,810		$	0.58		6.3	$	—
Granted		1,815,000		$	0.53		9.7	$	—
Expired		(6,261,308	)
Canceled		(77,837	)
Balance at June 30, 2015		9,749,665		$	0.61		7.9	$	—
Vested and Exercisable at June 30, 2015		3,940,489		$	0.74		6.7	$	—

The valuation methodology used to determine the fair value of the Options issued was the Black-Scholes Model.

The assumptions used in the Black-Scholes Model are set forth in the table below.

	Six Months   Ended June 30, 2015			Year Ended   December 31, 2014
Risk-free interest rate		1.41-1.47	%		1.59-1.83	%
Volatility		71.30-71.86	%		72.82-75.42	%
Expected life in years		6			6
Dividend yield		0.00	%		0.00	%

The risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the expected term of the Option and is calculated by using the average daily historical stock prices through the day preceding the grant date. Estimated volatility is a measure of the amount by which our stock price is expected to fluctuate each year during the expected life of the award. Our estimated volatility is an average of the historical volatility of our stock prices. Our calculation of estimated volatility is based on historical stock prices over a period equal to the expected life of the awards.

Share-based compensation expense for Options charged to our operating results for the six months ended June 30, 2015 and 2014 ($410,034 and $341,677, respectively) is based on awards vested. The estimate of forfeitures are to be recorded at the time of grant and revised in subsequent periods if actual forfeitures differ from the estimates. We have not included an adjustment to our stock based compensation expense based on the nominal amount of the historical forfeiture rate. We do, however, revise our stock based compensation expense based on actual forfeitures during each reporting period.

At June 30, 2015, total unrecognized estimated compensation expense related to non-vested Options granted prior to that date was approximately 1,469,000, which is expected to be recognized over a weighted-average period of 1.9 years. No tax benefit was realized due to a continued pattern of operating losses.

XML

AGREEMENT WITH HEALTHCOR (Details Narrative)						3 Months Ended			6 Months Ended		60 Months Ended
	Feb. 17, 2015 USD ($) $ / shares shares	Dec. 04, 2014 USD ($) $ / shares shares	Jan. 16, 2014 USD ($) $ / shares shares	Jan. 31, 2012 USD ($) $ / shares	Apr. 21, 2011 USD ($) $ / shares shares	Jun. 30, 2015 USD ($)	Mar. 31, 2015 USD ($) $ / shares shares	Jun. 30, 2014 USD ($)	Jun. 30, 2015 USD ($) Number	Jun. 30, 2014 USD ($)	Apr. 20, 2021	Apr. 20, 2016	Dec. 31, 2014 USD ($)	Aug. 19, 2013 USD ($)
Senior secured convertible notes						$ 30,914,930			$ 30,914,930
Minimum cash balance required under existing loan documents			$ 5,000,000			2,000,000			2,000,000					$ 5,000,000
Beneficial conversion features for senior secured convertible notes									928,256	$ 1,442,385
Interest Expense						2,217,846		$ 2,054,421	4,263,747	4,031,872
Senior Secured Convertible Notes [Member]
Debt discount						22,467,023			22,467,023				$ 21,457,970
2014 HealthCor Warrants [Member]
Debt discount						1,093,105			1,093,105
HealthCor Hybrid Offshore Master Fund [Member]
Senior secured convertible notes			$ 2,671,000	$ 2,671,000	$ 10,684,000
Debt Maturity Date			Jan. 15, 2024	Jan. 30, 2022	Apr. 20, 2021
Warrants issued for financing costs, warrants | shares					6,294,403
Exercise price of warrants | $ / shares					$ 1.40
Increase in interest rate (per annum) should default occur				5.00%
Debt conversion rate | $ / shares				$ 1.25
HealthCor Partners Fund [Member]
Senior secured convertible notes				$ 2,329,000	$ 9,316,000
Debt Maturity Date			Jan. 15, 2024	Jan. 30, 2022	Apr. 20, 2021
Warrants issued for financing costs, warrants | shares					5,488,456
Exercise price of warrants | $ / shares					$ 1.40
HealthCor Purchase Agreement [Member
Warrants issued for financing costs, warrants | shares			4,000,000
Exercise price of warrants | $ / shares			$ 0.40
Increase in interest rate (per annum) should default occur					5.00%
Debt conversion rate | $ / shares					$ 1.25
Minimum cash balance required under existing loan documents						2,000,000			2,000,000
Beneficial conversion features for senior secured convertible notes						471,268		416,689	928,255	817,384
Interest Expense						558,797		$ 535,833	$ 1,110,863	$ 1,064,251
HealthCor Purchase Agreement [Member | Senior Secured Convertible Notes [Member]
Interest rate, provided no default											10.00%	12.50%
Number of shares the note may be converted into | Number									26,808,000
HealthCor Purchase Agreement [Member | Senior Convertible Notes - 2012 Issuance [Member]
Number of shares the note may be converted into | Number									6,090,000
HealthCor Purchase Agreement [Member | Senior Convertible Notes - 2014 Issuance [Member]
Number of shares the note may be converted into | Number									14,954,000
HealthCor Purchase Agreement (the "Fourth Amendment") [Member
Senior secured convertible notes			$ 5,000,000
Debt conversion rate | $ / shares			$ 0.40
HealthCor Purchase Agreement (the "Fourth Amendment") [Member | Senior Convertible Notes - 2014 Issuance [Member]
Warrants issued for financing costs, warrants | shares			4,000,000
HealthCor Purchase Agreement (the "Fifth Amendment") [Member]
Senior secured convertible notes	$ 6,000,000	$ 6,000,000
Warrants issued for financing costs, warrants | shares		3,692,308
Debt conversion rate | $ / shares	$ 0.52	$ 0.52
Number of shares the note may be converted into | Number									2,012,000
Debt discount						$ 1,146,732			$ 1,146,732
HealthCor Purchase Agreement (the "Fifth Amendment") [Member] | Senior Convertible Notes - 2014 Issuance [Member]
Warrants issued for financing costs, warrants | shares	3,692,307
HealthCor Purchase Agreement New Investors (the "Fifth Amendment") [Member]
Number of shares the note may be converted into | Number									10,061,000
HealthCor Purchase Agreement (the "Sixth Amendment") [Member]
Warrants issued for financing costs, warrants | shares							1,000,000
Debt conversion rate | $ / shares							$ 0.53
Beneficial conversion features for senior secured convertible notes							$ 2,000,000

XML

BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS (Details 1) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Change in Fair Value of Level 3 Liabilities
Change in fair value of warrant liability	$ 225,147	$ 55,801	$ (12,954)	$ (577,341)
Significant Other Unobservable Inputs (Level 3) [Member]
Change in Fair Value of Level 3 Liabilities
Balance, beginning			(301,864)
Change in fair value of warrant liability			(12,954)
Balance, ending	$ (314,818)		$ (314,818)

XML

BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS (Details) - USD ($)	Jun. 30, 2015	Dec. 31, 2014	Dec. 31, 2013
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of warrant liability	$ (314,818)	$ (301,864)	$ (370,865)
Recurring Measurement [Member] | Significant Other Unobservable Inputs (Level 3) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of warrant liability	(314,818)
Recurring Measurement [Member] | Fair Value [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of warrant liability	$ (314,818)

XML

AGREEMENT WITH PDL BIOPHARMA, INC. (Details Narrative) - PDL BioPharma, Inc (Administrative Agent and Lender) [Member] - USD ($)

6 Months Ended

Jun. 26, 2015

Jun. 30, 2015

Debt face amount

$ 40,000,000

Description of payment terms

Principal repayment under each of Tranche One and Tranche Two will commence on the ninth interest payment date. We may elect to pay a portion of the interest due in the form of additional loans during the first eight interest payment dates. Each tranche will mature on the fifth anniversary of the date borrowed. We may elect to prepay the Loans at any time without any premium or penalty, subject to certain conditions.

Description of collateral

Secured by a pledge of substantially all of the assets of the Company and certain of its domestic subsidiaries.

Warrants [Member]

Number common stock called

4,444,445

Exercise price (in dollars per shares)

$ 0.45

Warrant expiration date

Jun. 26, 2025

Fair value

$ 1,257,778

Amortized interest expense

2,431

Deferred financing costs

746,811

Amortized deferred financing costs

1,464

Tranche One Debt [Member]

Debt face amount

$ 20,000,000

Description of debt milestone placement

In the event that a milestone relating to the placement of 9,000 billable units occurs on or before October 31, 2015,

Interest rate

13.50%

Tranche Two Debt [Member]

Debt face amount

$ 20,000,000

Description of debt milestone placement

(i) the placement of 27,750 billable units and (ii) the Company recording earnings before interest, tax, depreciation, and amortization (EBITDA) of not less than $7,000,000 on an annualized basis for the three calendar month period prior to the funding (on or before June 30, 2017),

Interest rate

13.00%

XML

LIQUIDITY AND MANAGEMENTS PLAN (Details Narrative) - USD ($)	Jun. 30, 2015	Jun. 26, 2015	Dec. 31, 2014	Jun. 30, 2014	Jan. 16, 2014	Dec. 31, 2013	Aug. 19, 2013
Cash and cash equivalents	$ 5,245,503		$ 2,546,262	$ 6,240,392		$ 4,125,180
Minimum cash balance required under existing loan documents	2,000,000				$ 5,000,000		$ 5,000,000
PDL BioPharma, Inc (Administrative Agent and Lender) [Member]
Debt face amount		$ 40,000,000
PDL BioPharma, Inc (Administrative Agent and Lender) [Member] | Tranche One Debt [Member]
Debt face amount	20,000,000
PDL BioPharma, Inc (Administrative Agent and Lender) [Member] | Tranche Two Debt [Member]
Debt face amount	$ 20,000,000

XML

STOCKHOLDERS' EQUITY (Details Narrative) - USD ($)					3 Months Ended	6 Months Ended
	Feb. 25, 2015	Feb. 17, 2015	Dec. 04, 2014	Jan. 16, 2014	Mar. 31, 2015	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014	Mar. 31, 2014	Dec. 31, 2013
Senior secured convertible notes						$ 30,914,930
Fair value of warrant liability						$ 314,818		$ 301,864		$ 370,865
2015 Stock Option Plan [Member]
Common stock shares reserved for future issuance	5,000,000
Options vesting period	3 years
Options exercise period	10 years
Options granted						1,815,000	1,300,000
Options cancelled						77,837	15,000
Options expired						6,261,308	41,666
Share-based compensation expense						$ 410,034	$ 341,677
Unrecognized estimated compensation expense						$ 1,469,000
Period for recognization of unrecognized compensation expense						1 year 10 months 24 days
HealthCor Purchase Agreement (the "Fifth Amendment") [Member]
Senior secured convertible notes		$ 6,000,000	$ 6,000,000
Fair value of convertible debt		$ 7,336,615
Warrants issued for financing costs, warrants			3,692,308
Debt conversion rate		$ 0.52	$ 0.52
Fair value of the warrants		$ 1,093,105
Unamortized debt discount						$ 1,146,732
HealthCor Purchase Agreement (the "Fifth Amendment") [Member] | Senior Convertible Notes - 2014 Issuance [Member]
Warrants issued for financing costs, warrants		3,692,307
HealthCor Purchase Agreement (the "Fourth Amendment") [Member
Senior secured convertible notes				$ 5,000,000
Fair value of convertible debt				$ 6,488,000
Debt conversion rate				$ 0.40
Fair value of the warrants				$ 1,146,732
HealthCor Purchase Agreement (the "Fourth Amendment") [Member | Senior Convertible Notes - 2014 Issuance [Member]
Warrants issued for financing costs, warrants				4,000,000
Purchase Agreement Warrants [Member]
Warrants outstanding					100,000
Warrants expired						2,892,686
Warrant exercise price					$ 0.53
Warrant expiration date					Mar. 31, 2025
Fair value of warrant liability					$ 378,000
Private Placement Warrants Revalued [Member]
Fair value of warrants at re-value						$ 314,818			$ 948,206
Fair value adjustment recorded as non-cash costs						12,954	$ 577,341
PDL BioPharma, Inc (Administrative Agent and Lender) [Member] | Warrant [Member]
Fair value of the warrants						$ 1,257,778
Warrant exercise price						$ 0.45
Warrant expiration date						Jun. 26, 2025
Number common stock called						4,444,445

XML

LIQUIDITY AND MANAGEMENT'S PLAN

6 Months Ended

Jun. 30, 2015

Liquidity And Managements Plan

LIQUIDITY AND MANAGEMENT'S PLAN

NOTE 2 – LIQUIDITY AND MANAGEMENT’S PLAN

Our cash position at June 30, 2015 was approximately $5,246,000.

Pursuant to the terms of a Note and Warrant Purchase Agreement dated April 21, 2011 (as subsequently amended) with HealthCor Partners Fund, LP and HealthCor Hybrid Offshore Master Fund, LP (“HealthCor”) we are required to maintain a minimum cash balance $2,000,000 (see NOTE 11 for further details), and we are in compliance with the minimum cash balance as of the date of this filing.

Our continued successful operation is dependent upon us achieving positive cash flow through operations while maintaining adequate liquidity. We expect that the cash on hand, as well as our existing and projected cash flow from billable contracts, will enable us to continue to operate for the next twelve month period. We believe that our sales and marketing plan to attract new business and our ongoing deployment and installation of units under existing hospital agreements, will meet our near-term cash needs and will help us achieve future operating profitability.

At present, we have sufficient inventory to install and service a select number of large customers, but eventually we will need to address additional capital requirements. To that end, on June 26, 2015, we entered into a Credit Agreement with PLD Biopharma, Inc., as administrative agent and lender (“the Lender”), (the “PDL Credit Agreement”) pursuant to which the Lender made available to us up to $40 million in two tranches of $20 million each, with each tranche contingent upon us meeting certain milestones (see NOTE 12 for further details). No funds were available on the PDL Credit Agreement at June 30, 2015.

XML

STOCKHOLDERS' EQUITY (Details) - Stock Options [Member] - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Number Options
Stock Options Outstanding, Beginning	14,273,810
Granted	1,815,000
Expired	(6,261,308)
Cancelled	(77,837)
Stock Options Outstanding, Ending	9,749,665	14,273,810
Stock Options, vested and exercisable	3,940,489
Weighted Average Exercise Price
Stock Options Outstanding, Beginning	$ 0.58
Granted	0.53
Stock Options Outstanding, Ending	0.61	$ 0.58
Stock Options, vested and exercisable	$ 0.74
Weighted Average Remaining Contractual Life
Stock Options Outstanding	7 years 10 months 24 days	6 years 3 months 18 days
Granted	9 years 8 months 12 days
Stock Options, vested and exercisable	6 years 8 months 12 days

XML

JOINT VENTURE AGREEMENT (Details Narrative)		6 Months Ended		12 Months Ended
	Nov. 16, 2009 USD ($) shares	Jun. 30, 2015 USD ($)	Jun. 30, 2014 USD ($)	Dec. 31, 2012 USD ($) Number	Dec. 31, 2014 USD ($)
Amortization of debt discount		$ 1,110,863	$ 1,064,250
Other current liabilities		1,121,259			$ 791,284
Joint Venture - Rockwell [Member]
Percentage owned by company of each joint venture	50.00%
Funding by Rockwell into the Joint Venture, cash	$ 1,151,205
Promissory note amounts	575,603	1,108,000
Investment Interest issued to Rockwell as Preferential Return	$ 575,602
Interest rate on project notes and preferential returns, per investment agreement	10.00%
Fair value of warrants issued to Rockwell for providing funding		$ 25,327
Discount on debt recorded	$ 636,752
Monthly revenue lost due to Hillcrest termination				$ 20,000
De-installation costs incurred				$ 3,000
Number of units remaining at Hillcrest site | Number				100
Other current liabilities				$ 10,250
Joint Venture - Rockwell [Member] | Warrants [Member]
Warrants issued for financing costs, warrants | shares	1,151,206
Fair value of warrants issued to Rockwell for providing funding	$ 1,124,728

XML

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Current Assets:
Cash	$ 5,245,503	$ 2,546,262
Accounts receivable, net of allowance for doubtful accounts	889,731	680,143
Other current assets	350,216	276,910
Total current assets	6,485,450	3,503,315
Property and equipment, net	5,042,805	5,344,792
Other Assets:
Intangible assets, net	293,958	261,283
Other assets	3,188,107	832,930
Total other assets	3,482,065	1,094,213
Total assets	15,010,320	9,942,320
Current Liabilities:
Accounts payable	511,294	244,782
Notes payable	441,594	441,594
Mandatorily redeemable equity in joint venture	441,594	441,594
Accrued interest	225,226	191,596
Other current liabilities	1,121,259	791,284
Total current liabilities	2,740,967	2,110,850
Long-term Liabilities:
Senior secured convertible notes, net of debt discount and debt issuance costs of $22,467,023 and $21,457,970, respectively	30,914,930	22,834,641
Fair value of warrant liability	314,818	301,864
Total long-term liabilities	31,229,748	23,136,505
Total liabilities	$ 33,970,715	$ 25,247,355
Commitments and Contingencies
Stockholders' Deficit:
Preferred stock - par value $0.001; 20,000,000 shares authorized; no shares issued and outstanding
Common stock - par value $0.001; 300,000,000 shares authorized; 139,380,748 issued and outstanding	$ 139,381	$ 139,381
Additional paid in capital	80,570,085	76,502,913
Accumulated deficit	(99,200,548)	(91,510,720)
Total CareView Communications Inc. stockholders' deficit	(18,491,082)	(14,868,426)
Noncontrolling interest	(469,313)	(436,609)
Total stockholders' deficit	(18,960,395)	(15,305,035)
Total liabilities and stockholders' deficit	$ 15,010,320	$ 9,942,320

XML

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
CASH FLOWS FROM OPERATING ACTIVITES
Net loss	$ (7,722,532)	$ (7,878,412)
Adjustments to reconcile net loss to net cash flows used in operating activities:
Depreciation	838,300	792,540
Provision for doubtful accounts	5,588
Amortization of debt discount	1,110,863	1,064,250
Amortization of installation costs	168,607	212,186
Amortization of intangible assets	19,852	14,168
Amortization of prepaid expense	15,915
Amortization of deferred debt issuance costs	2,431	284,692
Interest incurred and paid in kind	3,089,342	2,458,994
Stock based compensation related to options granted	410,033	341,677
Change in fair value of warrant liability	12,954	577,341
Loss on disposal of fixed assets	43,740
Changes in operating assets and liabilities:
Accounts receivable	(215,176)	(140,447)
Other current assets	(73,306)	(66,596)
Other assets	(747,283)	124,928
Accounts payable	266,512	(195,610)
Accrued expenses and other current liabilities	363,605	102,796
Other liabilities		(8,607)
Net cash flows used in operating activities	(2,410,555)	(2,316,100)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property and equipment	(580,053)	(308,465)
Payment for deferred installation costs	(159,069)	(242,566)
Patent and trademark costs	(52,527)	(9,458)
Software and website costs		(6,349)
Net cash flows used in investing activities	(791,649)	(566,838)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from notes and loans payable, net	5,901,445	5,000,000
Repayment of notes and loans payable		(1,850)
Net cash flows provided by financing activities	5,901,445	4,998,150
Increase in cash	2,699,241	2,115,212
Cash, beginning of period	2,546,262	4,125,180
Cash, end of period	5,245,503	6,240,392
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid for interest	10,170	$ 70,261
Cash paid for income taxes
SUPPLEMENTAL SCHEDULE OF NON-CASH FINANCING ACTIVITIES:
Beneficial conversion features for senior secured convertible notes	928,256	$ 1,442,385
Warrants issued in connection with the credit facility	1,257,778
Warrants issued in connection with the senior secured convertible notes	$ 1,471,105	$ 1,146,732

XML

PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 838,300	$ 792,540

XML

OTHER CURRENT ASSETS (Tables)

6 Months Ended

Jun. 30, 2015

Other Current Assets Tables

Schedule of other current assets

Other current assets consist of the following:

	June 30, 2015		December 31, 2014
Prepaid expenses	$	350,087	$	254,998
Other current assets		129		21,912
TOTAL OTHER CURRENT ASSETS	$	350,216	$	276,910

XML

PROPERTY AND EQUIPMENT (Details) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 11,692,947	$ 11,221,949
Less: accumulated depreciation	(6,650,142)	(5,877,157)
Property and equipment, net	5,042,805	5,344,792
Network Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	11,139,319	10,753,542
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	176,126	160,890
Vehicles [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	164,501	132,797
Test Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	115,540	87,059
Furniture [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	75,673	75,673
Warehouse Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	8,440	6,867
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 13,348	$ 5,121

XML

OTHER ASSETS (Tables)

6 Months Ended

Jun. 30, 2015

Other Assets Tables

Schedule of intangible assets

Intangible assets consist of the following:

	June 30, 2015
	Cost		Accumulated Amortization		Net
Patents and trademarks	$	323,669	$	42,354	$	281,315
Other intangible assets		51,464		38,821		12,643
TOTAL INTANGIBLE ASSETS	$	375,133	$	81,175	$	293,958

	December 31, 2014
	Cost		Accumulated Amortization		Net
Patents and trademarks	$	271,142	$	26,157	$	244,985
Other intangible assets		51,464		35,166		16,298
TOTAL INTANGIBLE ASSETS	$	322,606	$	61,323	$	261,283

Schedule of other assets

Other assets consist of the following:

	June 30, 2015
	Cost		Accumulated Amortization		Net
Deferred debt issuance costs	$	1,257,778	$	2,431	$	1,255,347
Prepaid financing costs		1,133,480		15,915		1,117,565
Deferred installation costs		1,616,167		1,034,254		581,913
Prepaid license fee		249,999		62,841		187,158
Security deposit		46,124		—		46,124
TOTAL OTHER ASSETS	$	4,303,548	$	1,115,441	$	3,188,107

	December 31, 2014
	Cost		Accumulated Amortization		Net
Deferred installation costs	$	1,457,098	$	865,647	$	591,451
Prepaid license fee		249,999		54,644		195,355
Security deposit		46,124		—		46,124
TOTAL OTHER ASSETS	$	1,753,221	$	920,291	$	832,930

XML

BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

6 Months Ended

Jun. 30, 2015

Accounting Policies [Abstract]

BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

NOTE 1 – BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

Interim Financial Statements

The accompanying unaudited interim condensed consolidated financial statements of CareView Communications, Inc. (“CareView”, the “Company”, “we”, “us” or “our”) have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, such financial statements include all adjustments (consisting solely of normal recurring adjustments) necessary for the fair statement of the financial information included herein in accordance with GAAP and the rules and regulations of the Securities and Exchange Commission (the “SEC”). The balance sheet at December 31, 2014 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by GAAP for complete financial statements. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the period. Actual results could differ from those estimates. Results of operations for interim periods are not necessarily indicative of results for the full year. The accompanying condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2014 as filed with the SEC on March 31, 2015.

Fair Value of Financial Instruments

Our financial instruments consist primarily of receivables, accounts payable, accrued expenses and short- and long-term debt. The carrying amount of receivables, accounts payable and accrued expenses approximates our fair value because of the short-term maturity of such instruments. We have elected not to carry our debt instruments at fair value. The carrying amount of our debt approximates fair value. Interest rates that are currently available to us for issuance of short- and long-term debt with similar terms and remaining maturities are used to estimate the fair value of the our short- and long-term debt and would be considered Level 3 inputs under the fair value hierarchy.

We have categorized our assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy in accordance with GAAP. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3).

Assets and liabilities recorded in the condensed consolidated balance sheets at fair value are categorized based on a hierarchy of inputs, as follows:

Level 1 -	Unadjusted quoted prices in active markets for identical assets or liabilities.
Level 2 -	Quoted prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument.
Level 3 -	Unobservable inputs for the asset or liability.

The Company’s financial assets and liabilities recorded at fair value on a recurring basis include the fair value of warrant liability as detailed below. The fair value of this warrant liability is included in long-term liabilities on the accompanying condensed consolidated financial statements.

The following table provides the financial assets and liabilities reported at fair value and measured on a recurring basis:

Description	Assets/   (Liabilities)   Measured at Fair Value			Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Other Unobservable Inputs (Level3)
Fair value of warrant liability	$	(314,818	)	$	—	$	—	$	(314,818	)

The following table provides a summary of changes in fair value associated with the Level 3 liabilities for the six months ended June 30, 2015:

	Fair Value Measurements Using Significant Unobservable Inputs (Level3)
Balance at January 1, 2015	$	(301,864	)
Issuances of derivative liabilities		—
Change in fair value of warrant liability		(12,954	)
Transfers in and/out of Level 3		—
Ending balance at June 30, 2015	$	(314,818	)

The above table of Level 3 liabilities begins with the prior period balance and adjusts the balance for changes that occurred during the current period. The ending balance of the Level 3 securities presented above represent our best estimates and may not be substantiated by comparisons to independent markets and, in many cases, could not be realized in immediate settlement of the instruments.

Earnings Per Share

We calculate earnings per share (“EPS”) in accordance with GAAP, which requires the computation and disclosure of two EPS amounts, basic and diluted. Basic EPS is computed based on the weighted average number of shares of common stock outstanding during the period. Diluted EPS is computed based on the weighted average number of common shares outstanding plus all potentially dilutive common shares outstanding during the period under the treasury stock method. Such potential dilutive common shares consist of stock options, warrants and convertible debt. Potential common shares totaling 110,516,873 and 91,270,341 at June 30, 2015 and 2014, respectively, have been excluded from the diluted earnings per share calculation as they are anti-dilutive due to our reported net loss.

Recently Issued and Newly Adopted Accounting Pronouncements

In April 2015, the Financial Accounting Standards Board (“FASB”), issued Accounting Standards Update (“ASU”) No. 2015-03, Interest-Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs. ASU 2015-03 requires that debt issuance costs be reported in the balance sheet as a direct deduction from the face amount of the related liability, consistent with the presentation of debt discounts and further requires the amortization of debt issuance cost to be reported as interest expense. Similarly, debt issuance costs and any discount or premium are considered in the aggregate when determining the effective interest rate of the debt. ASU 2015-03 is effective for fiscal years beginning after December 15, 2015 and interim periods within those fiscal years. Early adoption is permitted for annual or interim reporting periods for which the financial statements have not previously been issued. Management has opted for early adoption of ASU 2015-03 and there was no material effect on the consolidated financial statements upon adoption.

There have been no material changes to our significant accounting policies as summarized in NOTE 2 of our Annual Report on Form 10-K for the year ended December 31, 2014. We do not expect that the adoption of any recent accounting pronouncements will have a material impact on our accompanying condensed consolidated financial statements.

Reclassifications

Certain 2014 amounts have been reclassified to conform to current year presentation.

XML

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	20,000,000	20,000,000
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	139,380,748	139,380,748
Common stock, shares outstanding	139,380,748	139,380,748
Senior Secured Convertible Notes [Member]
Debt discount (in dollars)	$ 22,467,023	$ 21,457,970

XML

AGREEMENT WITH HEALTHCOR

6 Months Ended

Jun. 30, 2015

Agreement With Healthcor

AGREEMENT WITH HEALTHCOR

NOTE 11 – AGREEMENT WITH HEALTHCOR

On April 21, 2011, we entered into a Note and Warrant Purchase Agreement (as subsequently amended) (the “HealthCor Purchase Agreement”) with HealthCor. Pursuant to the HealthCor Purchase Agreement, we sold Senior Secured Convertible Notes to HealthCor in the principal amount of $9,316,000 and $10,684,000, respectively (collectively the “2011 HealthCor Notes”). The 2011 HealthCor Notes have a maturity date of April 20, 2021. We also issued Warrants to HealthCor for the purchase of an aggregate of up to 5,488,456 and 6,294,403 shares, respectively, of our Common Stock at an exercise price of $1.40 per share (collectively the “2011 HealthCor Warrants”).

So long as no event of default has occurred, the outstanding principal balances of the 2011 HealthCor Notes accrue interest from April 21, 2011 through April 20, 2016 (the “First Five Year Note Period”) at the rate of 12.5% per annum, compounding quarterly and shall be added to the outstanding principal balances of the 2011 HealthCor Notes on the last day of each calendar quarter. Interest accruing from April 21, 2016 through April 20, 2021 (the “Second Five Year Note Period”) at a rate of 10% per annum, compounding quarterly, may be paid quarterly in arrears in cash or, at our option, such interest may be added to the outstanding principal balances of the 2011 HealthCor Notes on the last day of each calendar.

From the date any event of default occurs, the interest rate, then applicable, shall be increased by five percent (5%) per annum. HealthCor has the right, upon an event of default, to declare due and payable any unpaid principal amount of the 2011 HealthCor Notes then outstanding, plus previously accrued but unpaid interest and charges, together with the interest then scheduled to accrue (calculated at the default rate described in the immediately preceding sentence) through the end of the First Five Year Note Period or the Second Five Year Note Period, as applicable.

At any time after April 21, 2011, HealthCor is entitled to convert any portion of the outstanding and unpaid accrued interest on and principal balances of the 2011 HealthCor Notes into fully paid and non-assessable shares of our Common Stock at a conversion rate of $1.25 per share, subject to adjustment in accordance with anti-dilution provisions set forth in the 2011 HealthCor Notes. As of June 30, 2015, the underlying shares of our Common Stock related to the 2011 HealthCor Notes totaled approximately 26,808,000.

On January 31, 2012, we entered into the Second Amendment to the HealthCor Purchase Agreement with HealthCor (the “Second Amendment”) amending the HealthCor Purchase Agreement, and sold Senior Secured Convertible Notes to HealthCor in the principal amounts of $2,329,000 and $2,671,000, respectively (collectively the “2012 HealthCor Notes”). As provided by the Second Amendment, the 2012 HealthCor Notes are in substantially the same form as the 2011 HealthCor Notes, with changes to the “Issuance Date,” “Maturity Date,” “First Five Year Note Period” and other terms to take into account the timing of the issuance of the 2012 HealthCor Notes. The 2012 HealthCor Notes have a maturity date of January 30, 2022. In addition, the provisions regarding interest payments, interest acceleration, optional conversion, negative covenants, and events of default, preemptive rights and registration rights are the same as those of the 2011 HealthCor Notes. At any time after January 30, 2012, HealthCor is entitled to convert any portion of the outstanding and unpaid accrued interest on and principal balances of the 2012 HealthCor Notes into fully paid and non-assessable shares of our Common Stock at a conversion rate of $1.25 per share, subject to adjustment in accordance with anti-dilution provisions set forth in the 2012 HealthCor Notes. As of June 30, 2015, the underlying shares of our Common Stock related to the 2012 HealthCor Notes totaled approximately 6,090,000.

On August 20, 2013, we entered into a Third Amendment to the HealthCor Purchase Agreement with HealthCor (the “Third Amendment”) to redefine our minimum cash balance requirements. Previously we were required to maintain a minimum cash balance of $5,000,000 and should we drop below that balance, it triggered a default. The Third Amendment allowed for a reduced minimum cash period, as defined in the HealthCor Purchase Agreement, which allowed us to drop below $5,000,000, but not below $4,000,000. All other terms and conditions of the HealthCor Purchase Agreement, including all amendments thereto, remain the same. Upon entering the reduced minimum cash period (which occurred on October 7, 2013), we had 120 days to return our minimum cash balance to the original $5,000,000. On January 16, 2014, we increased our cash balance to in excess of the original $5,000,000 minimum allowable balance.

On January 16, 2014, we entered into a Fourth Amendment to the HealthCor Purchase Agreement with HealthCor (the “Fourth Amendment”) and sold Senior Secured Convertible Notes to HealthCor in the principal amounts of $2,329,000 and $2,671,000 (collectively the ‘‘2014 HealthCor Notes’’). As provided by the Fourth Amendment, the 2014 HealthCor Notes are in substantially the same form as the 2011 HealthCor Notes, with changes to the “Issuance Date,” “Maturity Date,” “First Five Year Note Period” and other terms to take into account the timing of the issuance of the 2014 HealthCor Notes. The 2014 HealthCor Notes have a maturity date of January 15, 2024. In addition, the provisions regarding interest payments, interest acceleration, optional conversion, negative covenants, and events of default, preemptive rights and registration rights are the same as those of the 2011 HealthCor Notes. At any time after January 16, 2014, HealthCor is entitled to convert any portion of the outstanding and unpaid accrued interest on and principal balances of the 2014 HealthCor Notes into fully paid and non-assessable shares of our Common Stock at a conversion rate of $0.40 per share, subject to adjustment in accordance with anti-dilution provisions set forth in the 2014 HealthCor Notes. Additionally we issued Warrants to HealthCor for the purchase of an aggregate of up to 4,000,000 shares of our Common Stock at an exercise price of $0.40 per share (collectively the “2014 HealthCor Warrants”). As of June 30, 2015, the underlying shares of our Common Stock related to the 2014 HealthCor Notes totaled approximately 14,954,000.

On December 4, 2014, we entered into a Fifth Amendment to the HealthCor Purchase Agreement (the “Fifth Amendment”) with HealthCor and certain additional investors (such additional investors, the “New Investors” and, collectively with HealthCor Partners Fund, LP, the “Investors”) and agreed to sell and issue (i) additional notes in the initial aggregate principal amount of $6,000,000,with a conversion price per share of $0.52 (subject to adjustment as described therein) (the “Fifth Amendment Notes”) and (ii) additional Warrants for an aggregate of up to 3,692,308 shares of our Common Stock at an exercise price per share of $0.52 (subject to adjustment as described therein) (the “Fifth Amendment Warrants”). As provided by the Fifth Amendment, the Fifth Amendment Notes are in substantially the same form as the 2011 HealthCor Notes, with changes to the “Issuance Date,” “Maturity Date,” “First Five Year Note Period” and other terms to take into account the timing of the issuance of the Fifth Amendment Notes. The 2014 HealthCor Notes have a maturity date of February 16, 2025. In addition, the provisions regarding interest payments, interest acceleration, optional conversion, negative covenants, and events of default, preemptive rights and registration rights are the same as those of the 2011 HealthCor Notes. The New Investors are composed of all but one of our current directors and one of our officers. On February 17, 2015, the Company and the Investors closed on the transactions contemplated by the Fifth Amendment. In connection with this closing, the Company and the Investors entered into an Amended and Restated Pledge and Security Agreement (the “Amended Security Agreement”), amending and restating that certain Pledge and Security Agreement dated as of April 20, 2011, and an Amended and Restated Intellectual Property Security Agreement (the “Amended IP Security Agreement”), amending and restating that certain Intellectual Property Security Agreement dated as of April 20, 2011. As of June 30, 2015, the underlying shares of our Common Stock related to the Fifth Amendment Notes totaled approximately 2,012,000 to HealthCor and 10,061,000to the New Investors.

On March 31, 2015, we entered into the Sixth Amendment to the HealthCor Purchase Agreement (the “Sixth Amendment”) pursuant to which, among other things, (i) the requirement to maintain a minimum cash balance of $5,000,000 was reduced to a minimum cash balance of $2,000,000 and (ii) the amendment provision was revised to permit the HealthCor Purchase Agreement to be amended by the Company and the holders of the majority of the Common Stock underlying the outstanding notes and warrants to purchase shares of our Common Stock sold pursuant to the HealthCor Purchase Agreement. On March 31, 2015, we also issued a warrant to HealthCor to purchase up to an aggregate of 1,000,000 shares of our Common Stock in consideration for certain prior waivers of the minimum cash balance requirement in the HealthCor Purchase Agreement (the “Sixth Amendment Warrant”). The Sixth Amendment Warrant has an exercise price per share of $0.53 (subject to adjustment as described therein) and an expiration date of March 31, 2025.

On June 26, 2015, we (i) entered into a Seventh Amendment to the HealthCor Purchase Agreement (the “Seventh Amendment”) pursuant to which the HealthCor Purchase Agreement was amended to permit the Company to enter into and perform its obligations under the Credit Agreement entered into with PDL BioPharma, Inc., as administrative agent and lender (the “Lender”) (the “PDL Credit Agreement”); (ii) executed an Amendment to the Registration Rights Agreement between the Company and HealthCor dated April 21, 2011 (the “RR Agreement”) pursuant to which the RR Agreement was amended to make its priority of registration consistent with the Registration Rights Agreement executed by the Company and Lender (as detailed in NOTE 12); (iii) amended the 2011 HealthCor Notes to extend the maturity date, in the event that Tranche Two of the PDL Credit Agreement is funded, for such notes to 90 days after the earlier of the Tranche Two maturity date or repayment date, but not later than December 31, 2022, (iv) amended the 2012 HealthCor Notes, to set the maturity date at January 30, 2022 and, in the event that Tranche Two of the PDL Credit Agreement is funded, to extend such maturity date to 90 days after the earlier of the Tranche Two maturity date or repayment date, but later than December 31, 2022; and (v) amended each of the Senior Secured Convertible Notes issued under the HealthCor Purchase Agreement (the “HealthCor Notes”)to, among other things, subordinate the HealthCor Notes to the loans under the PDL Credit Agreement (as detailed in NOTE 12) and to increase certain event of default acceleration and payment thresholds.

Accounting Treatment

When issuing debt or equity securities convertible into common stock at a discount to the fair value of the common stock at the date the debt or equity financing is committed, a company is required to record a beneficial conversion feature (“BCF”) charge. We had three separate issuances of equity securities convertible into common stock that qualify under this accounting treatment, (i) the 2011 HealthCor Notes, (ii) the 2012 HealthCor Notes and (iii) the 2014 HealthCor Notes. Because the conversion option and the 2011 HealthCor Warrants on the 2011 HealthCor Notes were originally classified as a liability when issued and, subsequently reclassified to equity on December 31, 2011 when the 2011 HealthCor Notes were amended, only the accrued interest capitalized as payment in kind (‘‘PIK’’) since reclassification qualifies under this accounting treatment. The face amount of the 2012 and 2014 HealthCor Notes and all accrued PIK interest also qualify for this accounting treatment. During the three and six months ended June 30, 2015, we recorded a BCF of $471,268 and $928,255, respectively, and during the three and six months ended June 30, 2014, we recorded a BCF of $416,689 and $817,384, respectively. The BCF was recorded as a charge to debt discount and a credit to additional paid in capital, with the debt discount, using the effective interest method, amortized to interest expense over the term of the notes. As Warrants were issued with the 2014 HealthCor Notes and the Fifth Amendment Notes, the proceeds were allocated to the instruments based on relative fair value. The value allocated to the 2014 HealthCor Warrants and the Fifth Amendment Notes were $1,146,732 and $1,093,105, respectively, which were recorded as a debt discount with the credit to additional paid in capital. The discount associated with the 2014 HealthCor Warrants and the Fifth Amendment Notes is amortized to interest expense using the effective interest method.

We recorded an aggregate of $558,797 and $1,110,863 in interest expense for the three and six months ended June 30, 2015, respectively, and $535,833 and $1,064,251 in interest expense for the three and six months ended June 30, 2014, respectively, related to this discount. The carrying value of the debt with HealthCor at June 30, 2015 approximates fair value as the interest rates used are those currently available to us and would be considered level 3 inputs under the fair value hierarchy.

XML

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2015	Aug. 14, 2015
Document And Entity Information
Entity Registrant Name	CareView Communications Inc
Entity Central Index Key	0001377149
Document Type	10-Q
Trading Symbol	crvw
Document Period End Date	Jun. 30, 2015
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		139,380,748
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2015

XML

AGREEMENT WITH PDL BIOPHARMA

6 Months Ended

Jun. 30, 2015

Notes to Financial Statements

AGREEMENT WITH PDL BIOPHARMA

NOTE 12 – AGREEMENT WITH PDL BIOPHARMA, INC.

On June 26, 2015, we entered into a Credit Agreement with PDL BioPharma, Inc., as administrative agent and lender (“the Lender”) (the “PDL Credit Agreement”). Under the PDL Credit Agreement the Lender made available to us up to $40 million in two tranches of $20 million each.

In the event that a milestone relating to the placement of 9,000 billable units occurs on or before October 31, 2015, the Lender will fund us $20 million (“Tranche One”). In the event that additional milestones relating to (i) the placement of 27,750 billable units and (ii) the Company recording earnings before interest, tax, depreciation, and amortization (EBITDA) of not less than $7,000,000 on an annualized basis for the three calendar month period prior to the funding (on or before June 30, 2017), the Lender will fund us an additional $20 million (“Tranche Two” and, together with Tranche One, the “Loans”). Outstanding borrowings under Tranche One bear interest at the rate of 13.5% per annum, payable quarterly in arrears. Outstanding borrowings under Tranche Two bear interest at the rate of 13.0% per annum, payable quarterly in arrears.

Principal repayment under each of Tranche One and Tranche Two will commence on the ninth interest payment date. We may elect to pay a portion of the interest due in the form of additional loans during the first eight interest payment dates. Each tranche will mature on the fifth anniversary of the date borrowed. We may elect to prepay the Loans at any time without any premium or penalty, subject to certain conditions.

The obligations under the PDL Credit Agreement are secured by a pledge of substantially all of the assets of the Company and certain of its domestic subsidiaries. We executed a Subordination and Intercreditor Agreement (the “Subordination and Intercreditor Agreement”), with the Lender, HealthCor and the New Investors (as defined in NOTE 11) pursuant to which we granted first-priority liens on our pledged assets to the Lender and second-priority liens on such pledged assets to HealthCor and the New Investors.

The PDL Credit Agreement contains customary affirmative covenants for transactions of this type and other affirmative covenants agreed to by the Company and the Lender, including, among others, the provision of annual and quarterly reports, maintenance of property, insurance, compliance with laws and contractual obligations and payment of taxes. The PDL Credit Agreement contains customary negative covenants for transactions of this type and other negative covenants agreed to by the Company and the Lender, including, among others, restrictions on the incurrence of indebtedness, the granting of liens, making restricted payments and investments, entering into affiliate transactions and transferring assets. The PDL Credit Agreement also provides for a number of customary events of default, including payment, bankruptcy, covenant, representation and warranty and judgment defaults.

Contemporaneously with the execution of the PDL Credit Agreement, we issued to the Lender a warrant to purchase 4,444,445 shares of our Common Stock at an exercise price of $0.45 per share, subject to adjustment as described therein (the “PDL Warrant”). The PDL Warrant expires on June 26, 2025.

In addition, contemporaneously with the execution of the PDL Credit Agreement the Company and the Lender executed (i) a Registration Rights Agreement pursuant to which the Company agreed to provide the Lender with certain registration rights with respect to the shares of Common Stock issuable upon exercise of the PDL Warrant (the “PDL RRA”), (ii) a Guarantee and Collateral Agreement (the “Guarantee and Collateral Agreement”) pursuant to which certain of our subsidiaries guaranteed the performance of our obligations under the PDL Credit Agreement and granted the Lender a security interest in such subsidiaries’ tangible and intangible assets securing our performance of the same, and (iii) a Patent Security Agreement and a Trademark Security Agreement pursuant to which we granted the Lender a security interest in a certain subsidiary’s tangible and intangible assets securing the performance of our obligations under the PDL Credit Agreement.

Accounting Treatment

In connection with the Credit Agreement, we issued the PDL Warrant to the Lender. The fair value of the PDL Warrant at issuance was $1,257,778 and has been recorded as deferred issuance costs in the accompanying condensed consolidated financial statements. These costs are amortized to interest expense using the straight line method over the term of the Credit Agreement. Through June 30, 2015, $2,431 was amortized to interest expense. The PDL Warrant has not been exercised. We also incurred certain financing costs totaling $746,811 in the accompanying condensed consolidated financial statements. These costs have been recorded as deferred financing costs and are being amortized to interest expense over the term of the Credit Agreement. Through June 30, 2015, $1,464 has been amortized.

XML

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Income Statement [Abstract]
Revenues, net	$ 1,266,391	$ 698,129	$ 2,266,945	$ 1,317,538
Operating expenses:
Network operations	1,304,973	811,178	2,135,067	1,412,400
General and administration	923,056	805,081	1,761,365	1,607,058
Sales and marketing	233,154	155,089	430,776	363,547
Research and development	306,445	232,168	531,641	400,829
Depreciation and amortization	442,248	407,376	858,152	806,708
Total operating expense	3,209,876	2,410,892	5,717,001	4,590,542
Operating loss	(1,943,485)	(1,712,763)	(3,450,056)	(3,273,004)
Other income and (expense)
Interest expense	(2,217,846)	(2,054,421)	(4,263,747)	(4,031,872)
Change in fair value of warrant liability	225,147	55,801	(12,954)	(577,341)
Interest income	1,342	963	2,485	1,962
Other income	615	549	1,740	1,843
Total other income (expense)	(1,990,742)	(1,997,108)	(4,272,476)	(4,605,408)
Loss before taxes	$ (3,934,227)	(3,709,871)	(7,722,532)	(7,878,412)
Provision for income taxes
Net loss	$ (3,934,227)	(3,709,871)	(7,722,532)	(7,878,412)
Net loss attributable to noncontrolling interest	(16,482)	(17,087)	(32,704)	(32,927)
Net loss attributable to CareView Communications, Inc.	$ (3,917,745)	$ (3,692,784)	$ (7,689,828)	$ (7,845,485)
Net loss per share attributable to CareView Communications, Inc., basic and diluted (in dollars per share)	$ (0.03)	$ (0.03)	$ (0.06)	$ (0.06)
Weighted average number of common shares outstanding, basic and diluted (in shares)	139,380,748	138,960,678	139,380,748	138,857,611

XML

OTHER ASSETS

6 Months Ended

Jun. 30, 2015

Other Assets:

OTHER ASSETS

NOTE 6 – OTHER ASSETS

Intangible assets consist of the following:

	June 30, 2015
	Cost		Accumulated Amortization		Net
Patents and trademarks	$	323,669	$	42,354	$	281,315
Other intangible assets		51,464		38,821		12,643
TOTAL INTANGIBLE ASSETS	$	375,133	$	81,175	$	293,958

	December 31, 2014
	Cost		Accumulated Amortization		Net
Patents and trademarks	$	271,142	$	26,157	$	244,985
Other intangible assets		51,464		35,166		16,298
TOTAL INTANGIBLE ASSETS	$	322,606	$	61,323	$	261,283

Other assets consist of the following:

	June 30, 2015
	Cost		Accumulated Amortization		Net
Deferred debt issuance costs	$	1,257,778	$	2,431	$	1,255,347
Prepaid financing costs		1,133,480		15,915		1,117,565
Deferred installation costs		1,616,167		1,034,254		581,913
Prepaid license fee		249,999		62,841		187,158
Security deposit		46,124		—		46,124
TOTAL OTHER ASSETS	$	4,303,548	$	1,115,441	$	3,188,107

	December 31, 2014
	Cost		Accumulated Amortization		Net
Deferred installation costs	$	1,457,098	$	865,647	$	591,451
Prepaid license fee		249,999		54,644		195,355
Security deposit		46,124		—		46,124
TOTAL OTHER ASSETS	$	1,753,221	$	920,291	$	832,930

XML

PROPERTY AND EQUIPMENT

6 Months Ended

Jun. 30, 2015

Property And Equipment

PROPERTY AND EQUIPMENT

NOTE 5 – PROPERTY AND EQUIPMENT

Property and equipment consist of the following:

	June 30, 2015			December 31, 2014
Network equipment	$	11,139,319		$	10,753,542
Office equipment		176,126			160,890
Vehicles		164,501			132,797
Test equipment		115,540			87,059
Furniture		75,673			75,673
Warehouse equipment		8,440			6,867
Leasehold improvements		13,348			5,121
		11,692,947			11,221,949
Less: accumulated depreciation		(6,650,142	)		(5,877,157	)
TOTAL PROPERTY AND EQUIPMENT	$	5,042,805		$	5,344,792

Depreciation expense for the six months ended June 30, 2015 and 2014 was $838,300 and $792,540, respectively.

At June 30, 2015, some portion of our network equipment is in excess of current requirements based on the recent level of installations. We have developed a program to deploy assets over the near term and believe no impairment exists at June 30, 2015. No estimate can be made of a range of amounts of loss that are reasonably possible should we not be successful.

XML

PROPERTY AND EQUIPMENT (Tables)

6 Months Ended

Jun. 30, 2015

Property And Equipment Tables

Schedule of property and equipment

Property and equipment consist of the following:

	June 30, 2015			December 31, 2014
Network equipment	$	11,139,319		$	10,753,542
Office equipment		176,126			160,890
Vehicles		164,501			132,797
Test equipment		115,540			87,059
Furniture		75,673			75,673
Warehouse equipment		8,440			6,867
Leasehold improvements		13,348			5,121
		11,692,947			11,221,949
Less: accumulated depreciation		(6,650,142	)		(5,877,157	)
TOTAL PROPERTY AND EQUIPMENT	$	5,042,805		$	5,344,792

XML

BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS (Policies)

6 Months Ended

Jun. 30, 2015

Accounting Policies [Abstract]

Interim Financial Statements

Interim Financial Statements

The accompanying unaudited interim condensed consolidated financial statements of CareView Communications, Inc. (“CareView”, the “Company”, “we”, “us” or “our”) have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, such financial statements include all adjustments (consisting solely of normal recurring adjustments) necessary for the fair statement of the financial information included herein in accordance with GAAP and the rules and regulations of the Securities and Exchange Commission (the “SEC”). The balance sheet at December 31, 2014 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by GAAP for complete financial statements. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the period. Actual results could differ from those estimates. Results of operations for interim periods are not necessarily indicative of results for the full year. The accompanying condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2014 as filed with the SEC on March 31, 2015.

Fair Value of Financial Instruments

Fair Value of Financial Instruments

Our financial instruments consist primarily of receivables, accounts payable, accrued expenses and short- and long-term debt. The carrying amount of receivables, accounts payable and accrued expenses approximates our fair value because of the short-term maturity of such instruments. We have elected not to carry our debt instruments at fair value. The carrying amount of our debt approximates fair value. Interest rates that are currently available to us for issuance of short- and long-term debt with similar terms and remaining maturities are used to estimate the fair value of the our short- and long-term debt and would be considered Level 3 inputs under the fair value hierarchy.

We have categorized our assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy in accordance with GAAP. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3).

Assets and liabilities recorded in the condensed consolidated balance sheets at fair value are categorized based on a hierarchy of inputs, as follows:

Level 1 -	Unadjusted quoted prices in active markets for identical assets or liabilities.
Level 2 -	Quoted prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument.
Level 3 -	Unobservable inputs for the asset or liability.

The Company’s financial assets and liabilities recorded at fair value on a recurring basis include the fair value of warrant liability as detailed below. The fair value of this warrant liability is included in long-term liabilities on the accompanying condensed consolidated financial statements.

The following table provides the financial assets and liabilities reported at fair value and measured on a recurring basis:

Description	Assets/   (Liabilities)   Measured at Fair Value			Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Other Unobservable Inputs (Level3)
Fair value of warrant liability	$	(314,818	)	$	—	$	—	$	(314,818	)

The following table provides a summary of changes in fair value associated with the Level 3 liabilities for the six months ended June 30, 2015:

	Fair Value Measurements Using Significant Unobservable Inputs (Level3)
Balance at January 1, 2015	$	(301,864	)
Issuances of derivative liabilities		—
Change in fair value of warrant liability		(12,954	)
Transfers in and/out of Level 3		—
Ending balance at June 30, 2015	$	(314,818	)

The above table of Level 3 liabilities begins with the prior period balance and adjusts the balance for changes that occurred during the current period. The ending balance of the Level 3 securities presented above represent our best estimates and may not be substantiated by comparisons to independent markets and, in many cases, could not be realized in immediate settlement of the instruments.

Earnings Per Share

Earnings Per Share

We calculate earnings per share (“EPS”) in accordance with GAAP, which requires the computation and disclosure of two EPS amounts, basic and diluted. Basic EPS is computed based on the weighted average number of shares of common stock outstanding during the period. Diluted EPS is computed based on the weighted average number of common shares outstanding plus all potentially dilutive common shares outstanding during the period under the treasury stock method. Such potential dilutive common shares consist of stock options, warrants and convertible debt. Potential common shares totaling 110,516,873 and 91,270,341 at June 30, 2015 and 2014, respectively, have been excluded from the diluted earnings per share calculation as they are anti-dilutive due to our reported net loss.

Recently Issued and Newly Adopted Accounting Pronouncements

Recently Issued and Newly Adopted Accounting Pronouncements

In April 2015, the Financial Accounting Standards Board (“FASB”), issued Accounting Standards Update (“ASU”) No. 2015-03, Interest-Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs. ASU 2015-03 requires that debt issuance costs be reported in the balance sheet as a direct deduction from the face amount of the related liability, consistent with the presentation of debt discounts and further requires the amortization of debt issuance cost to be reported as interest expense. Similarly, debt issuance costs and any discount or premium are considered in the aggregate when determining the effective interest rate of the debt. ASU 2015-03 is effective for fiscal years beginning after December 15, 2015 and interim periods within those fiscal years. Early adoption is permitted for annual or interim reporting periods for which the financial statements have not previously been issued. Management has opted for early adoption of ASU 2015-03 and there was no material effect on the consolidated financial statements upon adoption.

There have been no material changes to our significant accounting policies as summarized in NOTE 2 of our Annual Report on Form 10-K for the year ended December 31, 2014. We do not expect that the adoption of any recent accounting pronouncements will have a material impact on our accompanying condensed consolidated financial statements.

Reclassifications

Reclassifications

Certain 2014 amounts have been reclassified to conform to current year presentation.

XML

JOINT VENTURE AGREEMENT

6 Months Ended

Jun. 30, 2015

Joint Venture Agreement

JOINT VENTURE AGREEMENT

NOTE 9 – JOINT VENTURE AGREEMENT

On November 16, 2009, we entered into a Master Investment Agreement (the “Rockwell Agreement”) with Rockwell Holdings I, LLC, a Wisconsin limited liability (“Rockwell”). Under the terms of the Rockwell Agreement, we used funds from Rockwell to fully implement the CareView System™ in Hillcrest Medical Center in Tulsa, Oklahoma (“Hillcrest”) and Saline Memorial Hospital in Benton, Arkansas (“Saline”) (the “Project Hospital(s)”). CareView-Hillcrest, LLC and CareView-Saline, LLC were created as the operating entities for the Project Hospitals under the Rockwell Agreement (the “Project LLC(s) “).

Rockwell and the Company own 50% of each Project LLC. We contributed our intellectual property rights and hospital contract with each Project Hospital and Rockwell contributed cash to be used for the purchase of equipment for the Project LLCs. Rockwell provided $1,151,205 as the initial funding, $575,603 was provided under promissory notes (the “Project Notes”) and $575,602 was provided under an investment interest (“Rockwell’s Preferential Return”). We classified Rockwell’s Preferential Return as a liability since it represents an unconditional obligation by us and is recorded in mandatorily redeemable equity in joint venture on the accompanying consolidated financial statements. The Project Notes and Rockwell’s Preferential Returns both earn interest at the rate of ten percent (10%) and are secured by a security interest in all of the equipment in the Project Hospitals, intellectual property rights, and the Project Hospital Contract

In accordance with GAAP, we determined the Project LLCs are VIEs based on the fact that the total equity investment at risk was not sufficient to finance the entities activities without additional financial support. We consolidate the Project LLCs as we have the power to direct the activities and an obligation to absorb losses of the VIEs. We have no contractual liability to Rockwell with respect to the repayment obligations of the Project LLCs.

As additional consideration to Rockwell for providing the funding, we granted Rockwell Warrants to purchase 1,151,206 shares of our Common Stock on the date of the Rockwell Agreement, and using the Black-Scholes Model valued the Warrants at $1,124,728 (the “Project Warrant”). The Project Warrant is classified as equity and is included in additional paid-in-capital on the accompanying consolidated financial statements. We allocated the proceeds to the Project Warrant, the Project Notes and Preferential Returns based on the relative fair value. The originally recorded debt discount of $636,752 was amortized over the expected life of the debt and was fully amortized as of March 31, 2013.

Hillcrest notified us of its desire to terminate its hospital agreement effective January 27, 2012. This termination resulted in the loss of monthly revenue totaling approximately $20,000, which revenue was used to make payments on our indebtedness to Rockwell. To date, we have incurred system removal costs of approximately $3,000 for removing our equipment from the hospital premises. We currently have approximately 100 units remaining on site at Hillcrest. Included in other current liabilities in the accompanying consolidated financial statements is an allowance for system removal totaling $10,250 to reserve for the removal of the remaining units.

As of June 30, 2015, the Project LLCs’ indebtedness to Rockwell, including principal and interest totaled approximately $1,108,000. On March 18, 2014, the Project Notes and Rockwell’s Preferential Returns, previously due on June 30, 2014 (the “June 2014 extensions”), were extended to June 30, 2015. On February 19, 2015, the Project Notes and Rockwell’s Preferential Returns due dates were extended to June 30, 2016. In conjunction with an August 2013 extension of the due dates of the Project Notes and Rockwell’s Preferential Returns to December 31, 2013, the expiration date of the Project Warrant was also extended from November 16, 2014 to November 16, 2015. All other provisions of the Project Warrant remained unchanged. The Project Warrant were amended and revalued in August 2013 resulting in a $25,327 increase in fair value, which has been recorded as non-cash costs included in general and administration expense in the accompanying consolidated financial statements. CareView, as 50% owner of the LLCs, is currently negotiating with Rockwell to settle the debt of the LLCs through the issuance of shares of CareView’s Common Stock. Although CareView anticipates that this settlement will be forthcoming in the near future, CareView and the LLCs can give no assurances that a settlement will be negotiated, or if negotiated and settled, that it will be through the issuance of CareView’s Common Stock.

XML

OTHER CURRENT LIABILITIES

6 Months Ended

Jun. 30, 2015

Other Current Liabilities

OTHER CURRENT LIABILITIES

NOTE 7 – OTHER CURRENT LIABILITIES

Other current liabilities consist of the following:

	June 30, 2015		December 31, 2014
Accrued issuance costs	$	550,000	$	—
Accrued taxes		201,270		145,183
Accrued paid time off		89,359		87,319
Accrued travel and entertainment		79,097		35,000
Accrued insurance		75,832		—
Allowance for system removal		61,121		277,000
Accrued professional services		30,400		204,675
Other accrued liabilities		34,180		42,107
TOTAL OTHER CURRENT LIABILITIES	$	1,121,259	$	791,284

XML

INCOME TAXES

6 Months Ended

Jun. 30, 2015

Income Tax Disclosure [Abstract]

INCOME TAXES

NOTE 8 – INCOME TAXES

Deferred income tax assets and liabilities are determined based upon differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. We do not expect to pay any significant federal or state income tax for 2015 as a result of the losses recorded during the six months ended June 30, 2015 and the additional losses expected for the remainder of 2015 and net operating loss carry forwards from prior years. Accounting standards require the consideration of a valuation allowance for deferred tax assets if it is “more likely than not” that some component or all of the benefits of deferred tax assets will not be realized. As of June 30, 2015, we maintained a full valuation allowance for all deferred tax assets. Based on these requirements, no provision or benefit for income taxes has been recorded. There were no recorded unrecognized tax benefits at the end of the reporting period.

XML

VARIABLE INTEREST ENTITIES

6 Months Ended

Jun. 30, 2015

Variable Interest Entities

VARIABLE INTEREST ENTITIES

NOTE 10 – VARIABLE INTEREST ENTITIES

The Company consolidates VIEs of which it is the primary beneficiary. The liabilities recognized as a result of consolidating these VIEs do not necessarily represent additional claims on our general assets; rather, they represent claims against the specific assets of the consolidated VIEs. Conversely, assets recognized as a result of consolidating these VIEs do not represent additional assets that could be used to satisfy claims against our general assets.

The total consolidated VIE assets and liabilities reflected on our consolidated balance sheets at June 30, 2015 and December 31, 2014 are as follows:

	June 30, 2015		December 31, 2014
Assets
Cash	$	372	$	2,770
Receivables		4,731		2,365
Total current assets		5,103		5,135
Property, net		24,289		46,762
Total assets	$	29,392	$	51,897
Liabilities
Accounts payable	$	127,962	$	122,558
Accrued interest		225,226		191,596
Other current liabilities		25,101		24,889
Notes payable-LT		441,594		441,594
Mandatorily redeemable interest-LT		441,594		441,594
Total liabilities	$	1,261,477	$	1,222,231

The financial performance of the consolidated VIEs reflected on our condensed consolidated statements of operations for the six months ended June 30, 2015 and 2014 is as follows:

	June 30,
	2015			2014
Revenue	$	14,194		$	14,259
Network operations expense		8,328			8,337
General and administrative expense (cost recovery)		1,485			1,473
Depreciation		24,464			25,264
Total operating costs		34,277			35,074
Operating loss		(20,083	)		(20,815	)
Other expense		(45,296	)		(45,039	)
Loss before taxes		(65,379	)		(65,854	)
Provision for taxes		—			—
Net loss		(65,379	)		(65,854	)
Net loss attributable to noncontrolling interest		(32,689	)		(32,927	)
Net loss attributable to CareView Communications, Inc.	$	(32,689	)	$	(32,927	)

XML

OTHER CURRENT ASSETS (Details) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Other Assets:
Prepaid expenses	$ 350,087	$ 254,998
Other current assets	129	21,912
TOTAL OTHER CURRENT ASSETS	$ 350,216	$ 276,910

XML

STOCKHOLDERS' EQUITY (Tables)

6 Months Ended

Jun. 30, 2015

Stockholders Equity Tables

Schedule of stock option activity

A summary of our stock option activity and related information follows:

	Number of Shares Under Options			Weighted Average Exercise Price		Weighted   Average   Remaining   Contractual   Life		Aggregate Intrinsic Value
Balance at December 31, 2014		14,273,810		$	0.58		6.3	$	—
Granted		1,815,000		$	0.53		9.7	$	—
Expired		(6,261,308	)
Canceled		(77,837	)
Balance at June 30, 2015		9,749,665		$	0.61		7.9	$	—
Vested and Exercisable at June 30, 2015		3,940,489		$	0.74		6.7	$	—

Schedule of assumptions used in the Black-Scholes Model - Warrants and Options

The assumptions used in the Black-Scholes Model are set forth in the table below.

	Six Months   Ended June 30, 2015			Year Ended   December 31, 2014
Risk-free interest rate		1.41-1.47	%		1.59-1.83	%
Volatility		71.30-71.86	%		72.82-75.42	%
Expected life in years		6			6
Dividend yield		0.00	%		0.00	%

XML

VARIABLE INTEREST ENTITIES (Tables)

6 Months Ended

Jun. 30, 2015

Variable Interest Entities Tables

Schedule of VIE assets and liabilities and results of operations

The total consolidated VIE assets and liabilities reflected on our consolidated balance sheets at June 30, 2015 and December 31, 2014 are as follows:

	June 30, 2015		December 31, 2014
Assets
Cash	$	372	$	2,770
Receivables		4,731		2,365
Total current assets		5,103		5,135
Property, net		24,289		46,762
Total assets	$	29,392	$	51,897
Liabilities
Accounts payable	$	127,962	$	122,558
Accrued interest		225,226		191,596
Other current liabilities		25,101		24,889
Notes payable-LT		441,594		441,594
Mandatorily redeemable interest-LT		441,594		441,594
Total liabilities	$	1,261,477	$	1,222,231

The financial performance of the consolidated VIEs reflected on our condensed consolidated statements of operations for the six months ended June 30, 2015 and 2014 is as follows:

	June 30,
	2015			2014
Revenue	$	14,194		$	14,259
Network operations expense		8,328			8,337
General and administrative expense (cost recovery)		1,485			1,473
Depreciation		24,464			25,264
Total operating costs		34,277			35,074
Operating loss		(20,083	)		(20,815	)
Other expense		(45,296	)		(45,039	)
Loss before taxes		(65,379	)		(65,854	)
Provision for taxes		—			—
Net loss		(65,379	)		(65,854	)
Net loss attributable to noncontrolling interest		(32,689	)		(32,927	)
Net loss attributable to CareView Communications, Inc.	$	(32,689	)	$	(32,927	)

XML

VARIABLE INTEREST ENTITIES (Details) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Assets
Receivables	$ 889,731	$ 680,143
Total current assets	6,485,450	3,503,315
Property, net	5,042,805	5,344,792
Total assets	15,010,320	9,942,320
Liabilities
Accounts payable	511,294	244,782
Accrued interest	225,226	191,596
Other current liabilities	1,121,259	791,284
Total liabilities	33,970,715	25,247,355
Variable Interest Entity [Member]
Assets
Cash	372	2,770
Receivables	4,731	2,365
Total current assets	5,103	5,135
Property, net	24,289	46,762
Total assets	29,392	51,897
Liabilities
Accounts payable	127,962	122,558
Accrued interest	225,226	191,596
Other current liabilities	25,101	24,889
Notes payable-LT	441,594	441,594
Mandatorily redeemable interest-LT	441,594	441,594
Total liabilities	$ 1,261,477	$ 1,222,231

XML

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT (Unaudited) - 6 months ended Jun. 30, 2015 - USD ($)	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Noncontrolling Interest [Member]	Total
Balance at Beginning at Dec. 31, 2014	$ 139,381	$ 76,502,913	$ (91,510,720)	$ (436,609)	$ (15,305,035)
Balance at Beginning (in shares) at Dec. 31, 2014	139,380,748
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock options granted as compensation		410,033			410,033
Warrants issued in connection with the senior secured convertible notes		1,471,105			1,471,105
Warrants issued in connection with the credit facility		1,257,778			1,257,778
Beneficial conversion features for senior secured convertible notes		$ 928,256			928,256
Net loss			$ (7,689,828)	$ (32,704)	(7,722,532)
Balance at End at Jun. 30, 2015	$ 139,381	$ 80,570,085	$ (99,200,548)	$ (469,313)	$ (18,960,395)
Balance at End (in shares) at Jun. 30, 2015	139,380,748

XML

OTHER CURRENT ASSETS

6 Months Ended

Jun. 30, 2015

Other Current Assets

OTHER CURRENT ASSETS

NOTE 4 – OTHER CURRENT ASSETS

Other current assets consist of the following:

	June 30, 2015		December 31, 2014
Prepaid expenses	$	350,087	$	254,998
Other current assets		129		21,912
TOTAL OTHER CURRENT ASSETS	$	350,216	$	276,910

XML

BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS (Details Narrative) - shares	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Basis Of Presentation And Recently Issued Accounting Pronouncements Details Narrative
Potentially dilutive common shares	110,516,873	91,270,341

XML

OTHER ASSETS (Details 1) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Cost	$ 4,303,548	$ 1,753,221
Accumulated Amortization	1,115,441	920,291
Other assets	3,188,107	832,930
Deferred debt issuance costs [Member]
Cost	1,257,778
Accumulated Amortization	2,431
Other assets	1,255,347
Prepaid financing costs [Member]
Cost	1,133,480
Accumulated Amortization	15,915
Other assets	1,117,565
Deferred installation costs [Member]
Cost	1,616,167	1,457,098
Accumulated Amortization	1,034,254	865,647
Other assets	581,913	591,451
Prepaid license fee [Member]
Cost	249,999	249,999
Accumulated Amortization	62,841	54,644
Other assets	187,158	195,355
Security deposit [Member]
Cost	46,124	46,124
Other assets	$ 46,124	$ 46,124

XML

BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS (Tables)

6 Months Ended

Jun. 30, 2015

Accounting Policies [Abstract]

Schedule of financial assets and liabilities reported at fair value and measured on a recurring basis

The following table provides the financial assets and liabilities reported at fair value and measured on a recurring basis:

Description	Assets/   (Liabilities)   Measured at Fair Value			Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Other Unobservable Inputs (Level3)
Fair value of warrant liability	$	(314,818	)	$	—	$	—	$	(314,818	)

Schedule of summary of changes in fair value associated with the Level 3 liabilities

The following table provides a summary of changes in fair value associated with the Level 3 liabilities for the six months ended June 30, 2015:

	Fair Value Measurements Using Significant Unobservable Inputs (Level3)
Balance at January 1, 2015	$	(301,864	)
Issuances of derivative liabilities		—
Change in fair value of warrant liability		(12,954	)
Transfers in and/out of Level 3		—
Ending balance at June 30, 2015	$	(314,818	)